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Abstract
Migraine is a common disabling condition likely to be associated with dysfunction of 
brain pathways involved in pain and other sensory modalities. Functional brain 
imaging in acute migraine has proved challenging due to the logistic problems 
associated with an episodic condition although it has provided us with important 
insights into the pathophysiology of the condition. Since the seminal observation of 
brainstem activation in migraine there has only been a single case substantiating this 
finding.
Our objectives were, first, to test the hypothesis that brainstem activation could be 
detected in migraine and to refine the anatomical localisation with higher resolution 
positron emission tomography (PET) and more advanced analysis techniques. 
Secondly, we wanted to explore the glyceryl trinitrate (GTN) model of migraine 
further to determine reliability and reproducibility. Finally, using this model we 
wished to explore the issue of laterality in migraine and, in particular, how it relates to 
brainstem activation.
H2150-labelled PET was used to study acute migraine attacks occurring spontaneously 
in five migraineurs. Using GTN-triggered migraine twenty-four migraineurs (divided 
into three groups according to the site of their headache: right/ left/ bilateral) and eight 
controls were scanned. The data was analysed using statistical parametric mapping 
(SPM99).
Significant brainstem activation was seen in the dorsolateral pons (P < 0.05 after 
small volume correction) during the migraine state versus the pain-free state in both 
spontaneous and induced migraine groups. When the induced group was analysed 
separately, to investigate laterality, it was found that the dorsal pontine activation was
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ipsilateral in the right-sided and left-sided groups and bilateral in the bilateral 
headache group with a left-sided preponderance.
Looking at the GTN model, thirty-three of the forty-four patients administered GTN 
had a migraine attack fulfilling International Headache Society criteria. Twelve 
patients described typical premonitory symptoms, which have not been previously 
documented with GTN-induced migraine. A repeat attack was triggered in all subjects 
but one and laterality was also remarkably reproducible. In one case a visual aura was 
also triggered both times.
Our study shows that GTN-induced triggering is common in our patients, and 
remarkably reproducible.
Overall, our findings provide clear evidence for dorsal pontine activation in migraine, 
and reinforce the view that migraine is a subcortical disorder involving modulation of 
afferent neural traffic. The results also suggest that lateralisation of pain in migraine is 
due to lateralised brain dysfunction.
Ethics approval
The studies described in this thesis were approved by the joint Ethics Committee of 
the National Hospital for Neurology and Neurosurgery (UCLH NHS Trust) and the 
Institute of Neurology (UCL), London, UK.
3
Acknowledgements
I would like to thank my supervisors, Peter Goadsby and Holger Kaube for their 
support over the past three years and Paul Hammond and Phil Holland for their 
technical assistance. I would also like to thank the Migraine Trust and Migraine 
Action Association for assisting with the recruitment of subjects and the numerous 
migraineurs who kindly volunteered to participate in these studies. Finally, I wish to 
acknowledge the support given to me by my family, especially my husband.
4
CONTENTS
Abstract.................................................................................................................................2
Acknowledgements.............................................................................................................4
Publications......................................................................................................................... 7
List of Figures...................................................................................................................... 8
List of Tables..................................................................................................................... 10
List of Abbreviations....................................................................................................... 11
PART I. INTRODUCTION............................................................................................13
Chapter 1. Migraine....................................................................................................... 13
1.1 An historical perspective..................................................................................... 13
1.2 Current concepts.................................................................................................. 14
1.3 The anatomical structures relevant to migraine................................................20
1.4 Explaining the mechanisms of migraine............................................................30
Chapter 2. Functional Imaging.....................................................................................33
2.1 Techniques...........................................................................................................33
2.2 History of functional imaging in migraine........................................................43
2.3 Pain Processing and Functional Imaging..........................................................57
Chapter 3. Laterality of migraine headache................................................................ 61
Chapter 4. Glyceryl trinitrate (GTN): a human migraine model.............................. 63
PART II. METHODS......................................................................................................68
Chapter 5. PET data acquisition and analysis............................................................. 68
5.1. PE T ......................................................................................................................68
5.2. SPM...................................................................................................................... 69
PART III. CLINICAL STUDIES.................................................................................. 71
5
Chapter 6. Exploring GTN triggering of migraine..................................................... 71
Chapter 7. A PET study in spontaneous migraine...................................................... 86
Chapter 8. A PET study exploring the laterality of brainstem...................................98
activation in migraine using GTN.................................................................................98
Chapter 9. Occipital activation in GTN-induced migraine with aura..................... 118
PART IV. DISCUSSION...............................................................................................125
PART V. CONCLUSION............................................................................................. 142
REFERENCES................................................................................................................143
APPENDIX...................................................................................................................... 177
6
Publications
Papers
1. Afridi SK, Kaube, Goadsby PJ. Occipital activation in glyceryl-trinitrate induced 
migraine with visual aura. J Neurol Neurosurg Psychiatry 2005; 76:1158-60
2. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory 
symptoms in migraine. Pain 2004; 110(3):675-80
3. Afridi SK, Giffin NJ, Kaube H, Friston K, Ward N, Frackowiak RSJ, Goadsby PJ. 
A PET study in spontaneous migraine. Archives of Neurology 2005; 62:1270-5
4. Afridi SK, Matharu MS, Lee L, Kaube H, Friston K, Ward N, Frackowiak RSJ, 
Goadsby PJ. A PET study exploring the laterality of brainstem activation in migraine 
using glyceryl trinitrate. Brain 2005; 128: 932-9
Other papers arising during thesis period
1. Afridi S, Goadsby PJ. New onset migraine with a brainstem cavernous angioma.
J Neurol Neurosurg Psychiatry 2003;74:680-682.
2. Afridi S, Bacon CM, Bowling J, Goadsby PJ. Verapamil and lymphomatoid 
papulosis in chronic cluster headache. Journal of Neurology 2004;251(4):473-5.
3. Afridi S, Kaube H. Prophylactic therapy of migraine. Current Treatment Options in 
Neurology 2003 5:431-40
7
List of Figures
Figure 1.1
Figure 1.2 
Figure 1.3 
Figure 1.4
Figure 2.1 
Figure 2.2
Figure 2.3 
Figure 2.4 
Figure 5.1 
Figure 6.1 
Figure 7.1
Figure 7.2 
Figure 7.3 
Figure 8.1 
Figure 8.2
Figure 8.3
Frequency of aura symptoms taken from a study of 952 16
migraine patients
Descending modulation of nociception 26
The proposed link between CSD and trigeminovascular activation 31 
Proposed pathways for brainstem involvement in pathophysiology 32 
of migraine
Examples of spectra from H-MRS and P-MRS 40
An example of a design matrix incorporating 5 subjects with 2 42
conditions
Spreading suppression of cortical activation during migraine aura 46 
PET scan showing brainstem activation during migraine 49
Statistical analysis using SPM 69
Response to GTN trigger amongst different groups 81
Activation in the dorsal pons in the migraine state compared to 94 
inter-ictal state
Area of deactivation in migraine state compared to inter-ictal state 94 
Activation in the thalamus and insula in migraine state 94
Study Design 106
Activation of the dorsolateral pons in migraine patients during 107 
glyceryl trinitrate (GTN) triggered attack
Activation in migraine patients during GTN infusion and 108
8
non-specific headache compared to matched controls 
Figure 8.4 Activation of the ipsilateral pons in patients with right 109
and left-sided attacks
Figure 9 Right-sided occipital activation during visual aura 121
Figure 10.1 Brainstem structures and pathways involved in migraine 125
Figure 10.2 fMRI showing activation in trigeminal nuclei regions in 140
response to noxious heat stimuli 
Figure 10.3 Brainstem activation in migraine (and hemicrania continua) 141
9
List of Tables
Table 1.1 Premonitory symptoms in migraine 15
Table 2.1 Chemical shift values for selected resonances 40
Table 6.1 Subject characteristics 77
Table 6.2 Glyceryl trinitrate (GTN) triggered headache in controls 78
Table 6.3 Premonitory symptoms in glyceryl trinitrate 79
triggered migraine
Table 6.4 Comparison of responders and non-responders to 80
glyceryl trinitrate triggered migraine 
Table 7.1 Subject characteristics 90
Table 7.2 Areas of activation in migraine state compared to 91
inter-ictal state
Table 7.3 Area of deactivation in migraine state compared with 93
inter-ictal state
Table 8.1 Subject characteristics 110
Table 8.2 Main effect of migraine 113
Table 8.3 Site of brainstem activation in each migraine sub-group 114
10
List of Abbreviations
ATP Adenosine triphosphate
BBB Blood brain barrier
BOLD Blood oxygen level dependent
CGRP Calcitonin gene-related peptide
CNV Contingent negative variation
CSD Cortical spreading depression
cGMP Cyclic guanosine monophosphate
DR Dorsal raphe
DWI Diffusion weighted imaging
FHM Familial hemiplegic migraine
fMRI Functional magnetic resonance imaging
GTN Glyceryl trinitrate
H-MRS Proton magnetic resonance spectroscopy
IDAP Intensity dependence of auditory evoked potentials
IHS International headache society
LC Locus coeruleus
MRI Magnetic resonance imaging
MRS Magnetic resonance spectroscopy
11
NO Nitric oxide
NOS Nitric oxide synthase
NRM Nucleus raphe magnus
PAG Periaqueductal gray
PCr Creatine phosphate
PET Positron emission tomography
Pi Inorganic phosphate
P-MRS Phosphorous magnetic resonance spectroscopy
PVN Paraventricular nucleus
PWI Perfusion weighted imaging
rCBF Regional cerebral blood flow
REM Rapid eye movement
RVM Rostroventral medulla
SC Subcoeruleus
SCN Supraoptic nucleus
SPECT Single photon emission computerised tomography
SPM Statistical parametrical mapping
SUNCT Short-lasting unilateral neuralgiform headache attacks with
conjunctival injection and tearing 
SVC Small volume comparison
5-HT Serotonin
TNC Trigeminal nucleus caudalis
TP Total phosphate
12
PART I. INTRODUCTION
Chapter 1. Migraine
1.1 An historical perspective
Written accounts of headache have been found in ancient Sumerian, Egyptian and 
Greek sources. One-sided headache was described in relation to the ancient Egyptian 
god Horus. Galen, in the second century AD, introduced the term “hemicrania” for 
unilateral headache following on from Aretaeus of Cappadocia’s term “heterocrania”. 
“Hemicrania” was later transformed to the Old English “megrim” and the French 
“migraine”(Lance and Goadsby, 1998b).
Descriptions of other features of migraine include the Persian Avicenna’s observation 
that sound, light or smell could trigger a headache. Willis, in 1684, described trigger 
factors including wine, overeating, lying in the sun, passion and long-sleeping. He 
also comments on “ravenous hunger” as a premonitory symptom. Fordyce, in “De 
Hemicrania” (1758) also observed premonitory depression and polyuria during the 
attack as well as the menstrual association.
Early descriptions of aura were provided by Le Pois in 1618 in his description of 
transient unilateral sensory disturbance preceding the headache. Wepfer (1669) and 
Vater (1723) observed and described visual aura (Isler and Clifford-Rose, 2000). 
Fothergill later coined the term “fortification spectra”.
Galen thought that the throbbing pain originated from blood vessels and tension pain 
from tendons or nerves. Willis also linked intracranial vasoconstriction with 
subsequent dilatation, a concept that was later taken up by Wolff in the early twentieth 
century. This vascular theory dominated the scene but there were dissenters even in
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the nineteenth century. Liveing, in 1873, wrote about migraine as a “nerve-storm” 
raging within the brain (Liveing, 1873). Hughlings-Jackson (Schiller, 1975) and 
Gowers (Gowers, 1906) remarked on the similarities between migraine and epilepsy.
Following his investigations into the nature of headache Wolff believed that aura and 
headache were a result of vascular changes (Wolff, 1948). He attributed aura to 
cerebral vasoconstriction and ascribed the headache of migraine to dilatation and 
inflammation of the extracranial arteries with some contribution from the dural or 
meningeal arteries. For most of the twentieth century migraine was still thought of as 
a “vascular headache”. It has since been shown that this relationship does not hold 
true (Andersen et al., 1988; Olesen et al., 1990; Olesen et al., 1981) and that the 
vascular changes may be a consequence rather than a cause of pain (Goadsby and 
Edvinsson, 1993; Lambert et al., 1984; May et al., 1998b). As a result of increasing 
research into the field the vascular concept of headache has been transformed into a 
“neurovascular” concept suggesting that vessel change is driven by nerves.
1.2 Current concepts
Migraine is a common disorder affecting an estimated 10-15% of the population 
(Lipton et al., 2001; Rasmussen and Olesen, 1992; Steiner et al., 2003). The 
International Headache Society (IHS) created a classification system for headaches in 
1998 (Headache Classification Committee of the International Headache Society, 
1988) with the aim of standardisation of diagnosis and revised it recently (Headache 
Classification Committee of The International Headache Society, 2004). Appendix 1 
lists some of the current criteria for the diagnosis of migraine.
Migraine can be subdivided into the premonitory phase, the aura phase and the 
headache phase. Some migraineurs also experience a postdrome and feel tired,
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washed out or in other cases euphoric or energetic. This is followed by resolution of 
the attack.
Premonitory
The premonitory phase is experienced by between 7-88% of migraineurs (Blau, 1980; 
Russell et al., 1996; Waelkens, 1985). The estimates vary probably because the issue 
has not been systematically studied at a population level. The phase can start up to 48 
hours prior to headache onset and can include a number of symptoms (Table 1.1). 
These have been documented prospectively in a study using an electronic diary 
(Giffin et al., 2003) which also demonstrated that these symptoms may persist into the 
headache phase of the attack. It is postulated that there is hypothalamic involvement 
during this phase since many of the symptoms, such as hunger, thirst and increased 
urination, are thought to be related to posterior hypothalamic function. A recent study 
demonstrated evidence of hypothalamic activation following stimulation of the 
superior sagittal sinus in cats (Benjamin et al., 2004). In a placebo controlled study 
domperidone was found to prevent the migraine attack when administered during the 
premonitory phase (Waelkens, 1982). This has led to the suggestion that the 
dopaminergic system may be involved in or associated with migraine.
Table 1.1 Premonitory symptoms in migraine
Psychological Neurological General
Depression
Euphoria
Irritability
Hyperactivity
Difficulty concentrating
Photophobia
Phonophobia
Dysphasia
Yawning
Drowsiness
Neck stiffness 
Food cravings 
Thirst 
Urination 
Fluid retention 
Sluggishness
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Aura
The aura phase involves a transient neurological phenomenon and is present in 
approximately 30-40% of migraineurs (Launer et al., 1999; Stewart et al., 1994). The 
aura typically precedes the headache by 10 minutes on average (Kelman, 2004) but 
can also accompany the headache or, less commonly, follow the headache phase 
(Russell and Olesen, 1996). It can, in up to 33.5% of cases (Kelman, 2004), present 
without headache. The most common aura symptoms are visual symptoms such as 
fortification spectra, photopsia, or scotoma. The disturbance often tends to start at the 
centre of the visual field and propagates out towards the periphery over 5-15 minutes. 
More complicated visual phenomena such as visual distortions or hallucinations can 
also occur. Other symptoms include paraesthesia, dysarthria, dysphasia, weakness, 
ataxia and disturbed consciousness.
Visual aura N u m b n ess/ S p eech  D izzin ess
tingling difficulties
Aura type
■  absent, □  occasional, m frequent, □  very frequent.
Figure 1.1 Frequency of aura symptoms taken from a study of 952 migraine patients 
(Kelman, 2004)
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Lashley (Lashley, 1941) mapped the progression of his own visual aura, calculating 
that cortical function was affected at a rate of ~3mm/minute. Aura is thought to be the 
clinical correlate of cortical spreading depression (CSD), first described by Leao 
(Leao, 1944). The time course and progression of symptoms correlate well with the 
temporal and spatial pattern of CSD. CSD is an electrophysiological phenomenon 
producing a slowly (2-6 mm/min) propagating wave of neuronal depolarisation 
followed by a suppression of neural activity. It probably starts with a cellular efflux of 
potassium, leading to depolarisation and a period of relative electrical silence. 
Additional negative ion species, such as glutamate are released. The subsequent 
energy-dependent restitution of ion gradients eventually restores normal neuronal 
activity. The depolarisation-restoration process takes approximately 1.5 minutes so 
the wave is only 5mm deep (James et al., 2001). In animals susceptibility to CSD is 
increased by hypoxia and hypoglycaemia as well as by applying solutions with 
increased potassium content. Animal studies also reveal behavioural changes induced 
by CSD such as contralateral sensory neglect, yawning and drowsiness (Gorji, 2001; 
Huston, 1971). Looking at human studies, in addition to the evidence linking CSD 
and aura provided by imaging studies (described in chapter 2) including 
magnetoencephalography (Bowyer et al., 2001), recent genetic discoveries have 
strengthened this proposed link. In a knock-in mouse model carrying one of the 
human mutations for familial hemiplegic migraine (CACNA1A-RX92Q) the mice were 
found to have a reduced threshold and increased velocity of cortical spreading 
depression (Van Den Maagdenberg et al., 2004). In another group of FHM patients 
the mutation is on the ATP1A2 gene resulting in a loss of Na/K ATPase pump 
function (De Fusco et al., 2003). It is proposed that this loss of pump function may
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depolarise neurons and lead to impaired clearance of potassium by astrocytes and this, 
in turn, would facilitate CSD.
CSD does not respect vascular boundaries and results in vascular changes but not 
ischaemia (Hadjikhani et al., 2001). These will be discussed further in the light of 
imaging studies in section 2.
In a proportion of patients the aura is prolonged or persistent and in a sub-group of 
migraineurs the aura defines the condition as “hemiplegic migraine” (see appendix for 
diagnostic criteria).
Headache
The headache in migraine has certain characteristics and associated features:
A. Headache attacks lasting 4-72 hours and occurring < 15 days/month (untreated 
or unsuccessfully treated).
B. Headache has at least two of the following characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical activity
(i.e., walking or climbing stairs)
Adapted from IHS classification system (Headache Classification Committee of The 
International Headache Society, 2004).
Despite the origins of the word, migraine is bilateral in approximately one third of 
patients (Lance and Anthony, 1966). The location of the head pain is variable but 
typically affects the head, neck and face, most commonly the frontotemporal regions.
It has been documented to also affect the limbs in rare cases (Guiloff and Fruns,
1988). Migraineurs also often develop cutaneous allodynia which can extend outside 
the head to affect the limbs (Burstein et al., 2000).
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As to what causes the headache in migraine, this is a point of contention. The current 
theories will be discussed later.
There are a number of trigger factors which precipitate an attack in susceptible 
migraineurs. Common triggers include sleep disturbance, stress / relaxation after 
stress, hormonal changes and eating patterns. It is not known how these factors 
precipitate an attack.
Genetics
It has been observed from twin studies (Svensson et al., 2003) and epidemiological 
surveys that there is a strong genetic component to migraine. Simple Mendelian 
patterns of inheritance cannot explain the common versions of migraine, namely 
migraine with aura and migraine without aura. However, a relatively rare subtype, 
familial hemiplegic migraine (FHM) has been found to have an autosomal dominant 
pattern of inheritance. In 1996 the first FHM gene, CACNA1A, was identified on 
chromosome 19pl3. It encodes for the pore-forming (ona) sub-unit of Ca(v)2.1 (P/Q) 
calcium channels. This mutation is thought to account for 75% of FHM families (Kors 
et al., 2004). A second FHM gene, ATP1A2, has recently been identified on 
chromosome 1 (De Fusco et al., 2003). It encodes for the cm sub-unit of a sodium- 
potassium pump. These findings suggest that dysfunction of ion-channels are involved 
in the pathophysiology of migraine, or at least in hemiplegic migraine.
In addition to the findings in FHM, linkage studies have identified loci on 
chromosome 4, 6, 11 and 14 which are associated with the more common forms of
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migraine (Kors et al., 2004). This reinforces the view that there are a combination of 
genetic and environmental factors responsible for migraine with and without aura.
There is also evidence, mainly from magnetic resonance spectroscopy studies, to 
suggest that energy metabolism is dysfunctional in migraine. This will be detailed 
later. However no mitochondrial mutations have yet been found in migraineurs (Haan 
et al., 1999; Klopstock et al., 1996; Russell et al., 1997) although patients with 
mitochondrial disorders such as MELAS (mitochondrial encephalopathy with lactic 
acidosis and stroke-like episodes) have migraine as part of their disorder.
1.3 The anatomical structures relevant to migraine
Pain can be generated by large intracranial vessels, venous sinuses and by dural 
vessels (Ray and Wolff, 1940). These vessels are innervated by the ophthalmic 
division of the trigeminal nerve and the structures in the posterior fossa are innervated 
by C2 nerve root branches. Stimulation of vascular afferents leads to activation, with 
Fos protein expression, in the trigeminal nucleus caudalis (TNC) and in the dorsal 
horn at Cl and C2 (Goadsby and Hoskin, 1997; Kaube et al., 1993). Stimulation of 
the greater occipital nerve, a branch of C2, also leads to activation in this region 
(Goadsby et al., 1997). On this functional basis this area has been referred to as “the 
trigeminocervical complex”. The information is then relayed, via the quintothalamic 
tract, to the ventroposteromedial thalamus, medial nucleus of the posterior complex 
and the intralaminar thalamus (Zagami and Lambert, 1990). The trigeminal brainstem 
nuclei also have projections to the hypothalamus (Malick and Burstein, 1998) and 
other subcortical nuclei (Marfurt and Rajchert, 1991).
20
The anatomy o f  the brainstem monoaminergic systems
There is a significant body of evidence implicating the involvement of serotonin in 
migraine. During migraine platelet serotonin levels decrease rapidly and urinary 
excretion of 5-hydroxyindoleacetic acid, the main metabolite of serotonin (5-HT), 
increases (Curran et al., 1965). Pharmacological depletion of serotonin with agents 
such as reserpine can induce a migraine and serotonin itself can abort an attack 
(Kimball et al., 1960). The triptans and many of the migraine preventives work on 
5-HT receptors.
The brainstem serotonergic system is divided into two groups: the rostral group, 
confined to the midbrain and rostral pons, with major projections to the forebrain, and 
the caudal group, which extends from the caudal pons to the caudal medulla, with 
major projections to the caudal brainstem and spinal cord. Most neurons are located 
along the mid-line of the brainstem. The rostral group accounts for 85% of all 
serotonergic neurons in the brain and includes the dorsal raphe nucleus which extends 
from the oculomotor nucleus to the middle of the pons (Homung, 2003). The rostral 
group regulates the sleep-wake cycle, affective behaviour, food intake, 
thermoregulation and sexual behaviour. The caudal group includes the nucleus raphe 
magnus which projects to the spinal dorsal horn. This is involved in regulation of 
nociception.
There is limited evidence of differences in platelet and plasma levels of noradrenaline 
between migraineurs and controls when taking the menstrual cycle into account 
(D'Andrea et al., 2004). The noradrenergic neurons are separated into dorsal and 
ventral regions. The nucleus ambiguous, the nucleus of the solitary tract and the 
dorsal motor vagus nucleus are in the medulla. At the level of the pons the neurons in
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the ventrolateral reticular formation project to the spinal cord and modulate autonomic 
reflexes and pain sensation. The locus coeruleus (LC), which is situated dorsolaterally 
in the pons, is composed of 10-15,000 neurons and has extensive projections to the 
cerebral cortex, hypothalamus and cerebellum and descending projections to the 
brainstem and spinal cord (Willis and Westlund, 1997). The pericoerulear region 
receives input from the prefrontal cortex, amygdala, hypothalamus and dorsal raphe 
(Berridge and Waterhouse, 2003). Locus coeruleus neurons display tonic and phasic 
discharge activity patterns. The tonic activity is state-dependent: the highest discharge 
rates are during waking and lowest during sleep. Phasic discharges occur in response 
to novel stimuli and they habituate with repeated stimulus presentation. The locus 
coeruleus and its efferent projections are thought to play a role in sleep, vigilance, 
modulation of sensory neurons and control of cortical activation.
The dopaminergic system is mainly centred around the midbrain and includes the 
substantia nigra and ventral tegmental area. These provide ascending pathways to the 
cortex and basal ganglia which are important in the initiation of behavioural 
responses. Dopaminergic neurons in the hypothalamus send descending pathways to 
the spinal cord and are thought to be involved in autonomic and endocrine regulation 
(Kandel et al., 2000).
Brainstem modulation o f nociception and vascular control
Descending modulation of trigeminal nociception arises from the frontal cortex, 
insula, amygdala and hypothalamus and extends through the periaqueductal gray
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(PAG) and the rostral ventral medulla (RVM) to the superficial lamina of the 
trigeminocervical complex (Fields and Basbaum, 1999). The RVM includes the 
serotonergic nucleus raphe magnus (NRM) and adjacent reticular formation. The PAG 
has excitatory connections with the NRM (Behbehani and Fields, 1979) and it 
receives input from the locus coeruleus, nucleus cuneiformis and pontomedullary 
reticular formation. Stimulation of the PAG and RVM activates inhibitory 
intemeurons in the TNC via descending serotonergic pathways (Fields and Busbaum, 
1994). The pain-modulating action of the PAG is largely relayed via the RVM and is 
abolished by lesions in the NRM or pharmacological depletion of serotonin 
(Behbehani and Fields, 1979). Injection of opiods into the RVM or PAG leads to 
activation of “o ff’’cells and inhibition of “on” cells resulting in inhibition of 
nociception (Morgan and Fields, 1994). The “on” cells are thought to facilitate 
nociception and have been shown to be active during the hyperalgesia associated with 
naloxone-precipitated opiod withdrawal (Bederson et al., 1990). It is of interest to 
note that the activity of these “on” and “o ff’ cells is modulated by 5-HT i receptor 
agonists (Ellrich et al., 2001a; Roychowdhury and Heinricher, 1997).
It is known that the dorsolateral pontine tegmentum is also involved in nociception. It 
is directly linked to the PAG and RVM. The region incorporates the subcoeruleus 
(SC), the locus coeruleus (LC) and the Kolliker-Fuse nucleus. This area is the major 
source of noradrenergic innervation of the spinal cord and stimulation of this region 
produces antinociception (Jones, 1991). Electrophysiological experiments have shown 
that activation of the dorsolateral pontine tegmentum, either electrically or chemically 
can inhibit nociceptive activity in dorsal horn neurons, an effect which is mediated by 
a2 adrenoreceptors (Girardot et al., 1987; Yeomans et al., 1992). Electrical
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stimulation of the LC/SC produced a reduction in both spontaneous activity and 
responses of the rat TNC to somatic input, especially nociceptive input (Tsuruoka et 
al., 2003). Beta-adrenoreceptors are thought to be involved in this trigeminal neuronal 
inhibition (Sasa et al., 1986). Furthermore, electrical stimulation of this region has 
been shown to produce analgesia in patients with chronic pain (Young et al., 1992).
The parabrachial nuclei also have interconnections with the trigeminal nuclei and are 
thought to be involved in suppression of nociceptive firing from the TNC (Chiang et 
al., 1994).
Ascending nociceptive pathways may also be modulated. The locus coeruleus and 
dorsal raphe nucleus send noradrenergic and serotonergic projections, respectively to 
the forebrain which may inhibit nociception. Lesions of these nuclei are associated 
with a reduced antinociceptive effect of morphine and a reduction of forebrain 
noradrenaline and serotonin (Sandkuhler and Jensen, 2000).
In addition to modulation of nociception, the brainstem is also involved in influencing 
vascular changes. Stimulation of the main central noradrenergic nucleus, the locus 
coeruleus (LC), in animal studies reduces cerebral blood flow but increases external 
carotid flow in a frequency-dependent manner (Goadsby and Duckworth, 1987; 
Goadsby et al., 1982). In contrast, stimulation of the dorsal raphe increases cerebral 
blood flow in the monkey (Goadsby et al., 1985) and also leads to extracranial 
vasodilatation in the same manner as LC stimulation. This extracranial effect has been 
shown to be a parasympathetic response mediated via the release of vasoactive 
intestinal polypeptide (VIP) from the greater superficial petrosal branch of the facial
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nerve (Goadsby et al., 1983). This forms the efferent pathway of the “trigeminal- 
autonomic reflex”. The reflex can be activated by trigeminal afferent activation which 
then, via the superior salivatory nucleus in the pons, results in a cranial 
parasympathetic response mediated through the pterygopalatine ganglion.
Stimulation of the trigeminal ganglion also leads to the antidromic release of 
substance P and CGRP with a resultant increase in extracerebral blood flow (Lambert 
et al., 1984; Markowitz et al., 1987).
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Periaqueductal gray matter
MIDBRAIN
Nucleus raphe magnus
MEDULLA
Dosolateral funiculus
Dorsal root ganglion
SPINAL
CORD
Locus coeruleus
PONS
Figure 1.2 Descending modulation of nociception. Taken from (Kandel et al., 2000).
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Evidence for the role o f  the brainstem in migraine
The relevance of this system to migraine was first demonstrated clinically by Raskin 
and colleagues (Raskin et al., 1987). He described a sub-group of 15 patients from 
175 with no previous headache history who developed migrainous headaches 
following the implantation of stimulating electrodes into the periaqueductal gray. This 
observation has since been reproduced in another series of patients (Veloso et al., 
1998). There have also been case reports of new onset migraine following 
haemorrhage from brainstem (pontine) cavernous angiomata (Afridi and Goadsby, 
2003; Goadsby, 2002; Katsarava et al., 2003a). An imaging study revealed that the 
PAG of a group of migraineurs was found to have abnormally high levels of iron 
which was correlated with duration of illness (Welch et al., 2001). The PAG has also 
been shown to modulate trigeminovascular nociception in experimental animals 
(Knight and Goadsby, 2001) and this modulation is blocked after local blockade of 
the P/Q-type calcium channel with agatoxin (Knight et al., 2002). The clinical 
relevance of this finding is that the FHM type 1 gene mutation (CACNA1A) also 
affects the same P/Q- type calcium channels. It has also been shown that 
dihydroergotamine and triptans bind to receptor sites in the PAG (Goadsby and 
Gundlach, 1991; Goadsby and Knight, 1997). Moreover, in a recent study 
administration of naratriptan, a 5 -H T iB/id agonist, into the PAG elicited 
antinociceptive effects on dural input (Bartsch et al., 2004). This finding, along with 
the finding that naratriptan modulated neuronal activity in the nucleus raphe magnus 
(Ellrich et al., 2001a), suggests that triptans may partly work by altering brainstem 
modulation of nociception in migraine.
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There is a significant body of electrophysiological evidence supporting the role of the 
brainstem in migraine. Contingent negative variation (CNV) is an event related slow 
cerebral potential appearing in a reaction-time task between a warning and an 
imperative stimulus. There is an increased amplitude and lack of habituation in 
patients with migraine (Maertens de Noordhout et al., 1986) which is more 
pronounced for the early component thought to be modulated by noradrenergic 
systems. It also appears to be abnormal in non-migraineurs who have a family history 
of migraine (Siniatchkin et al., 2001). The CNV normalizes after treatment with (3- 
blockers (Maertens de Noordhout et al., 1987) and one study has suggested a 
significant correlation between CNV amplitude before treatment and therapeutic 
efficacy of propranolol (Schoenen et al., 1986). This inter-ictal lack of habituation has 
also been demonstrated with visual-evoked and auditory-evoked potentials (Schoenen, 
1998). The lack of habituation reverses during the migraine attack. Habituation is a 
complex phenomenon which is likely to be affected by the level of cortical 
preactivation excitability. This excitability is thought to be modulated by the 
brainstem monoaminergic systems (Hegerl and Juckel, 1993). Interestingly, a recent 
study showed that fluoxetine, a serotonin reuptake blocker, normalized the VEP 
habituation pattern in migraineurs (Ozkul and Bozlar, 2002). Another 
electrophysiological measure found to be abnormal inter-ictally in migraineurs is the 
intensity dependence of auditory evoked potentials (IDAP) (Wang et al., 1996). This 
is thought to be related to central serotonergic transmission. It is high in migraineurs 
which is compatible with low central serotonergic transmission (Hegerl and Juckel, 
1993) but it may also be a consequence of lack of habituation (Ambrosini et al.,
2003). It, too, is modulated by serotonergic modulators such as dexfenfluramine and 
triptans (Proietti-Cecchini et al., 1997) and by p-blockers (Sandor et al., 2000). The
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increased IDAP normalises just before and during the migraine attack (Judit et al., 
2000). It has been proposed that these electrophysiological changes reflect the 
fluctuations in serotonergic activity throughout the ictal and inter-ictal phases of 
migraine.
In addition to modulation of nociception, the brainstem serotonergic and 
noradrenergic systems are involved in the modulation of cortical activity and 
attentiveness to environmental stimuli (Berridge and Waterhouse, 2003; Matrenza et 
al., 2004; Parvizi and Damasio, 2003). This may help to explain the so-called 
associated symptoms of migraine, such as photophobia and phonophobia. The raphe 
and dorsolateral pontine tegmentum are thought to be involved in sleep and arousal 
(Jouvet, 1969; Morgane, 1981). Migraineurs often experience changes in levels of 
arousal during various phases of a migraine attack (Giffin et al., 2003) and sleep 
disturbance can trigger a migraine.
There is evidence that the blood-brain barrier (BBB) is abnormal in migraine (Harper 
et al., 1977). It has been shown that noradrenergic innervation arising from the locus 
coeruleus is essential for maintaining BBB integrity during some states (Harik and 
McGunigal, 1984) and that modulation of this system alters BBB permeability in 
animals (Preskom et al., 1980).
Neuroimaging has provided us with further evidence for a role for the brainstem. This 
is detailed in chapter 2.
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1.4 Explaining the mechanisms of migraine
There are currently two main schools of thought surrounding the pathophysiology of 
migraine which have incorporated various concepts, including central sensitisation, 
plasma protein extravasation, cortical spreading depression and brainstem modulation, 
to different extents. One school maintains that CSD initiates the migraine and that the 
process is driven by peripheral nerve fibre activation. The other focuses on the pivotal 
role of the brainstem and maintains that the process is centrally determined.
A link between CSD and trigeminovascular activation (Figure 1.3)
Supporters of this theory propose that CSD leads to the release of neurotransmitters, 
metabolites, potassium and hydrogen ions into the perivascular space resulting in 
transient hyperemia and vasodilatation of cerebral vessels. The molecules are also 
thought sensitize perivascular and dural trigeminal afferents (arrow 1 on Fig 1.3) and 
transmit impulses to the trigeminal ganglia and TNC (arrow 3, 4). It is then thought 
that inflammatory neuropeptide release (substance P, CGRP) results in plasma protein 
extravasation and neurogenic inflammation with subsequent sensitization of 
medullary dorsal horn neurons (Burstein et al., 2000) resulting in head pain. The 
ipsilateral TNC transmits impulses and stimulates the superior salivatory nucleus and 
parasympathetic efferents via the sphenopalatine ganglia leading to vasodilatation 
(trigeminoparasympathetic reflex) and release of nitric oxide or acetylcholine into the 
dura mater. In a study by the Moskowitz group (Bolay et al., 2002) middle meningeal 
artery blood flow elevation followed evoked CSD in an experimental model and 
CSD-induced plasma protein leakage was shown to be blocked by trigeminal 
denervation.
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This theory provides a plausible explanation for the link between migraine aura and 
headache but does not account for migraine without aura. Also the relationship
between aura and headache is not always straightforward. Clinical and experimental 
observations (Olesen et al., 1990; Selby and Lance, 1960) have shown that aura is not 
always contralateral to headache.
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Figure 1.3 The proposed link between CSD and trigeminovascular activation.
Adapted from (Bolay et al., 2002).
Brainstem theory (Figure 1.4)
The other theory proposes a more fundamental role for the brainstem in the process.
It is proposed that descending pathways from the cortex (stress), thalamus (excessive 
afferent stimulation, light, noise) or hypothalamus (sleep disturbance) project to the 
brainstem leading to activation of brainstem nuclei such as the dorsal raphe and locus 
coeruleus. The vascular changes associated with migraine occur as a result of this 
brainstem activation, namely LC induced cerebral vasoconstriction and DR stimulated 
dilatation as well as dilatation of the extracranial circulation mediated via the greater
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superficial petrosal nerve (the trigeminoparasympathetic reflex). As a result of 
activation of brainstem centres, probably the monoaminergic nuclei and other systems 
which are involved in the descending modulation of nociception such as the PAG and 
raphe nuclei, there is modulation of sensory input including the input from trigeminal 
afferents. Consequently, a normally innocuous stimulus, such as the pulsation of 
cerebral vessels, is perceived as a painful throbbing sensation.
Since the brainstem is also involved in modulation of cortical activity and 
attentiveness to environmental stimuli (Matrenza et al., 2004; Parvizi and Damasio, 
2003) this could also account for symptoms such as photophobia and phonophobia. 
Proponents of this theory maintain that CSD is a parallel process.
Cortot Dorsal raphe 
nucleus
Hypothalamus
/ P Superior ^-salivatory nucleusDura
Magnus raphe 
nucleus
Figure 1.4 Proposed pathways for brainstem involvement in pathophysiology of 
migraine. Taken from (Goadsby et al., 2002).
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Chapter 2. Functional Imaging
2.1 Techniques
In 1890 Charles Sherrington demonstrated that stimulation of the brain caused a local 
increase in blood flow. Functional imaging is based on the principle that local changes 
in cerebral blood flow or metabolism accompany alterations of brain function 
(Frackowiak and Friston, 1994). The metabolic changes in neurons and glia that 
accompany neurotransmitter release are energy requiring. Most of this energy is used 
at or around synapses. Normal brain energy production depends on oxidative 
metabolism. Thus, there is a greater local demand for oxygen and glucose with 
increased synaptic activity and to meet this demand there is an increase in local blood 
flow.
The functional coupling of regional cerebral blood flow (rCBF) and local cerebral 
glucose metabolism is well established (Jueptner and Weiller, 1995). The majority of 
glucose is needed for the maintenance of membrane potentials and restoration of ion 
gradients. Glucose utilization reflects synaptic activity.
The search for regionally specific effects is based on the concept of “functional 
segregation”. This states that cells with common functional properties are grouped 
together and this, in turn, necessitates both convergence and divergence of cortical 
connections. An example of this is found in the visual cortex. V2 has a distinctive 
cytochrome oxidase architecture, consisting of thick and thin stripes. Directionally 
selective cells are found in the thick stripes, exclusively. Retrograde labelling of cells 
in V5 is limited to these thick stripes. V5 is a functionally homogenous area, 
specialised for visual motion. Thus, if it is the case that neurons in a given area of the
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brain share a common responsiveness to some sensorimotor attribute, then this 
functional segregation is also an anatomical one.
The various functional imaging techniques, described below, are sensitive to different 
types of changes. The techniques have evolved over time resulting in improvements in 
spatial and temporal resolution.
Xenon blood flow studies and single photon emission computed tomography 
(SPECT)
The earliest attempts at functional imaging involved inhalation or intra-arterial 
injection of gamma emitting 133Xenon into the carotid artery. Cerebral blood flow was 
then detected by a gamma camera consisting of up to 254 stationary detectors 
covering one hemisphere. The measurements were repeated at 10-20 minute intervals. 
The numerous regional cerebral blood flow values (from each detector) were stored as 
a matrix and a flow distribution map created. The resultant spatial resolution was 1 - 
5cm.
Xenon inhalation has also been used in combination with SPECT. SPECT involves 
rotating gamma camera detectors which results in improved spatial and temporal 
resolution compared with stationary detectors. Even better spatial resolution can be 
obtained using intravenous technetium-99m hexamethylpropyleneamine oxime (99mTc 
HMPAO) as the tracer. This provides a semi-quantitative analysis of regional cerebral 
blood flow.
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Positron emission tomography (PET)
PET is a tomographic nuclear imaging procedure, which uses positrons as radiolabels 
and positron-electron annihilation reaction-induced gamma rays to locate the 
radiolabels. It can provide a quantitative measurement of blood flow and, therefore, 
represents an improvement since SPECT. In H2150  PET water is labelled with a 
positron emitter (lsO) and injected intravenously into the patient, who is scanned by 
the tomographic system. The l50  is generated in a cyclotron. The tracer has a half-life 
of 124 seconds. The image is obtained after an interval of 90 seconds during which 
the H2150  enters the brain. The scanner detects the spatial and temporal distribution of 
the radiolabel by detecting gamma rays during the so-called emission scan. The 
positron emitted by beta decay slows down to a slower speed. This is necessary for 
the annihilation reaction between the positron and a shell electron of a neighbouring 
atom to occur. The annihilation reaction produces two gamma rays which travel in 
almost exactly opposite directions (this is due to the conservation of energy and 
momentum laws). The two gamma rays are detected by a coincidence counting 
detection system as they register almost simultaneously on opposing pairs of 
scintillation detectors. This coincidence event identifies a line upon which the 
annihilation occurred. Absorption and scatter of photons by intervening tissue needs 
to be corrected for in order to obtain accurate measurements of tracer concentrations. 
This “attenuation correction” is performed by means of a transmission scan which is 
done prior to the emission scan. During this scan a positron-emitting source is placed 
around the body. From this source one of the annihilation photons has to travel the 
total distance through body tissues while the second photon is not attenuated at all. 
This allows attenuation factors to be derived.
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The PET scanner consists of multiple detector rings to scan a number of transaxial 
planes simultaneously. The detector rings are scintillation crystals (bismuth germinate 
or sodium iodide) which fluoresce when struck by ionising radiation. These 
scintillations are then converted to electronic signals. The collected raw data are 
reconstructed into a cross-sectional image. Usually data are acquired in a three- 
dimensional (3D) mode. The PET images are then coregistered with a structural scan,
usually an MRI, to enable accurate anatomical localization.
PET provides relatively good temporal resolution and spatial resolution when 
compared with SPECT. The temporal resolution is dependent on the time taken for 
the tracer to reach the brain (90 seconds) and on the half-life of the tracer (124 
seconds for l50). This enables the comparison of brain states such as migraine versus 
pain-free but is not fast enough to follow, for example, progression of migraine aura. 
The spatial resolution of PET is dependent upon the position and type of detectors.
The resultant nominal resolution for the scanner used in our studies is 6.4 ± 0.2 mm. 
PET can detect changes in regional CBF of 3-5%.
Magnetic resonance imaging (MRI)
This uses a strong magnetic field (BO field) and gradient fields to localize bursts of 
radiofrequency signals coming from a system of spins consisting of reorienting 
hydrogen nuclei (protons) after they have been disturbed by radiofrequency pulses 
(RE). MR imaging produces high resolution imaging and makes use of the fact that 
many nuclei exhibit a property called spin. These spins are orientated in an external 
magnetic field. External radiofrequency pulses disturb their orientated state and make
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them absorb energy, which is subsequently reradiated. The intensity of the reradiated 
signal is dependent on the radiating tissue and the pulse sequence used to disturb the 
spins.
“Relaxation” refers to the process by which spins release the energy of excitation and 
return to their original configuration. Relaxation times are measured for an entire 
collection of spins and are statistical or average measurements. The two measures of 
relaxation which describe energy transfer by the excited spin are T1 and T2. The 
differences in relaxation times between tissues are primarily responsible for contrast 
in MRI. The T1 relaxation time, also known as the longitudinal relaxation time or 
spin-lattice relaxation time, is the time for the magnetization to return to 63% of its 
original length. It is the mechanism by which the spins give up their energy to the 
surroundings to return to their equilibrium orientation. T2 relaxation, also known as 
transverse relaxation or spin-spin relaxation, occurs when spins in the low and high 
energy state exchange energy but do not lose energy to the surrounding lattice. T2 is 
the time when the transverse magnetization is 37% of its value immediately after the 
radiofrequency pulse.
Functional MRI (fMRI)
Blood Oxygen Level Dependent (BOLD) imaging allows detection of regional 
cerebral blow changes with a very high degree of temporal resolution. While 
oxyhaemoglobin has no substantial magnetic properties, deoxyhaemoglobin is 
strongly paramagnetic and can thus serve as an intrinsic paramagnetic contrast agent 
in appropriately performed MR imaging. If perfusion is increased by some means 
without increasing the local oxygen consumption, the venous oxyhaemoglobin 
concentration will increase and the deoxyhaemoglobin concentration will decrease.
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As a result, there is less paramagnetic influence of free iron on T2* relaxation in a 
tissue volume containing draining veins and there is a signal intensity increase. This 
indirect, qualitative measure of perfusion allows localization of brain regions that are 
activated.
Diffusion weighted imaging (DWI) detects net translational movement of water using 
diffusion-sensitizing magnetic field gradients to dephase and rephase the protons in 
water. A regional decrease of diffusion is visible as hyperintensity on DWI. It can 
detect cell swelling e.g. following ischaemic insults.
Perfusion weighted imaging (PWI) provides estimates of haemodynamic changes 
based on dynamic imaging during the injection of high-susceptibility paramagnetic 
contrast medium such as gadolinium. It is sensitive to changes occurring at the 
micro vascular level.
Magnetic resonance spectroscopy (MRS)
MRS is primarily employed as a technique which noninvasively monitors 
biochemistry in vivo. It uses nuclear magnetic resonance for the determination of 
individual chemical compounds. The underlying principle of MRS is that atomic 
nuclei are surrounded by a cloud of electrons which very slightly shield the nucleus 
from any external magnetic field. As the structure of the electron cloud is specific to 
an individual molecule or compound, the magnitude of this screening effect is also a 
characteristic of the chemical environment of individual nuclei. In view of the fact 
that the resonant frequency is proportional to the magnetic field that it experiences, it 
follows that the resonant frequency will be determined not only by the external 
applied field, but also by the small field shift generated by the electron cloud. This
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shift in frequency is called the chemical shift. It should be noted that chemical shift is 
a very small effect, usually expressed in "parts per million" (ppm) of the main 
frequency (Table 2.1). In order to resolve the different chemical species, it is therefore 
necessary to achieve very high levels of homogeneity of the main magnetic field BO. 
Spectra from humans usually require shimming the magnet to approximately one part 
in 108.
In the context of human MRS, two nuclei are of particular interest: !H and 31P. Proton 
MR Spectroscopy ^H-MRS) is mainly employed in studies of the brain where 
prominent peaks arise from N-acetylaspartate (NAA), choline-containing compounds, 
creatine and creatine phosphate (PCr), myo-inositol and, if present, lactate.
Phosphorous 31 MR Spectroscopy (31P-MRS) detects compounds involved in energy 
metabolism: creatine phosphate (PCr), adenosine triphosphate (ATP) and inorganic 
phosphate (Pi) and certain compounds related to membrane synthesis and degradation. 
The possibility of determining the intracellular concentrations of high energy (PCr 
and ATP) and low energy phosphates (Pi) offers information on the status of energy 
metabolism in tissues. The phosphorylation potential, an indication of the free energy 
available in tissue, can be calculated from the values of ATP, ADP and Pi. It is also 
possible to determine intracellular pH because the inorganic phosphate peak position 
is pH sensitive.
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Table 2.1 Chemical shift values for selected resonances.
Functional group/molecule Chemical shift (ppm)
Lactate, methyl group 1.3
N-Acetylaspartate (NAA) 2.0
Choline 3.2
a-ATP -7.8
/3-ATP -18.2
7-ATP -2.7
Pi, inorganic phosphate 5.2
Cr NAA
Cho
Pi PCr
ATP
Figure 2.1 Examples of spectra from ’H-MRS (top spectrum) and 31P-MRS.
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Statistical parametrical mapping (SPM)
Statistical parametric mapping refers to the construction and assessment of spatially 
extended statistical process used to test hypotheses about neuroimaging data from 
SPECT/PET and fMRL It is a voxel-based approach, employing classical inference, to 
make some comment about regionally specific responses to experimental factors or 
brain states. Images are spatially normalised into a standard space and smoothed. 
Parametric statistical models are assumed at each voxel, using the general linear 
model (GLM) to describe the variability in the data, in terms of experimental and 
confounding effects, and residual variability. The experimental design and model used 
to test for specific neurophysiological responses form a mathematical structure called 
“the design matrix”. This is partitioned according to whether the effect is of interest 
(e.g. an activation) or not (e.g. a nuisance effect). The contribution of each effect (i.e. 
each column of the design matrix) to the observed physiological responses is 
estimated using the general linear model and standard least squares. These estimated 
contributions are known as parameter estimates. Regionally specific effects are 
framed in terms of differences among these parameter estimates (e.g. an activation 
effect) and are specified using contrasts. The significance of each contrast is assessed 
with a statistic that has Student’s t distribution under the null hypothesis. For each 
contrast, or difference in parameter estimates, an SPM {t}statistic is computed for 
each voxel in the brain. This is transformed into a SPM {Z}. Statistical inferences are 
then made about local excursions of the SPM {Z} above a specified threshold, using 
the Gaussian field theory. These pertain to the maximal value and spatial extent of the 
observed activations. The resulting P values and the SPM {Z} scores are the end point 
of the analysis.
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Global CBF varies both between subjects and within subjects over time. For normal 
subjects the global CBF is measured as the mean rCBF over all voxels. The 
contribution o f  global CBF to the variance in regional CBF is removed by a voxel-by- 
voxel analysis o f  covariance (ANCOVA) with global CBF as the confounding 
variable. A map is created resulting in condition specific adjusted rCBF values 
normalised to a nominal mean global activity o f  50m l/100m g/m inute.
P ain  N o pain
1
3 
5 
7 
9 
11 
13 
1 5 
17 
19 
21 
23 
25 
27 
29 
31 
33 
35 
37
40
' IhP
Figure 2.2 An example o f  a design matrix incorporating 5 subjects with 2 conditions. 
The column above shows the contrast between condition 1 and condition 2.
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2.2 History of functional imaging in migraine
Functional imaging has been utilised to help characterize the underlying
pathophysiology of migraine.
In this section I will first discuss the results from imaging studies investigating 
migraine with aura and migraine without aura. I will then focus more specifically on 
the migraine aura and more complicated and rare forms of aura, namely prolonged 
and persistent aura. Finally I will review the results of MRS studies in migraine.
2.2.1 Migraine with and without aura
Migraine with aura 
Xenon /  SPECT
The earliest attempts at functional imaging in migraine tended to focus on the 
migraine aura. At the time W olffs theory of migraine was dominant. This proposed 
that migraine aura was caused by intracerebral vasoconstriction and that the headache 
was due to reactive vasodilatation of the carotid artery. In the early 1970’s Xenon 
flow imaging showed a reduction in cerebral blood flow during aura and 
hyperperfusion during the headache (O'Brien, 1971; Skinhoj, 1973). Attacks were 
triggered by carotid angiography and measurement intervals were between 15 and 30 
minutes. In 1981 another Xenon flow study showed that the vascular theory was not 
sufficient to explain migraine (Olesen et al., 1981). The study involved six 
migraineurs and used an improved detector unit. It showed that in three of the subjects 
the unilateral, focal (occipito-parietal) oligaemia during the aura was preceded by 
hyperemia. In 5 subjects the oligaemia spread anteriorly. What was particularly
43
interesting was that in 4 subjects severe headache was observed during the oligaemic 
phase. This observation was replicated by SPECT studies (Andersen et al., 1988; 
Friberg et al., 1991; Lauritzen and Olesen, 1984). The hyperemic phase has also been 
shown to persist beyond the headache phase (Andersen et al., 1988; Sakai and Meyer, 
1978). Therefore, vasodilatation could not explain the headache component of 
migraine.
fM Rl (BOLD)
A case report of a subject with migraine with aura scanned within 10 minutes of onset 
of his spontaneous aura (left, homonymous quadrantanopia) demonstrated an increase 
in T2 weighted contrast intensity bilaterally in the occipital cortex, the red nucleus 
and the substantia nigra (Welch et al., 1998). Following on from this twenty-six 
migraineurs (twenty-three with aura and three without aura) were scanned during 
repetitive visual stimulation, using a checkerboard stimulus, in order to trigger a 
migraine (Cao et al., 2002). Fifteen subjects (thirteen with aura and two without) 
developed either headache or aura or both. In 75% of these, baseline T2-weighted MR 
signal intensities increased in the red nucleus, substantia nigra and occipital cortex. In 
seven of the subjects signal increases were also detected in other brainstem structures 
including locus coeruleus, periaqueductal grey, pons and central midbrain, although 
the time course, duration and extent of activation in these structures is not 
documented. The same group then studied the occipital cortex in greater depth using 
the same stimulus (Cao et al., 1999). In five of twelve subjects the onset of headache 
or visual change was preceded by suppression of initial activation. The suppression 
propagated into contiguous occipital cortex at a rate of 3-6 mm/minute and was 
accompanied by baseline contrast intensity increases that indicated vasodilatation and
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hyperoxygenation. Interestingly, one of these five subjects had a diagnosis of 
migraine without aura. No clear evidence of ischaemia was noted in this study.
In a more detailed study of aura BOLD changes were recorded which suggested CSD 
was responsible for generating migraine aura (Hadjikhani et al., 2001). The study 
involved three subjects and five attacks of migraine with aura were studied, two 
induced by exercise and three spontaneous. Initially, a focal increase in BOLD signal 
(thought to reflect vasodilatation) developed within the extrastriate visual cortex. This 
signal then propagated contiguously at a rate of 3.5 ± 1.1 mm/min over the occipital 
cortex, congruent with the retinotopy of the visual percept (Figure 2.3). The BOLD 
signal then diminished possibly reflecting vasoconstriction. The spreading 
phenomenon did not cross prominent sulci and were restricted to the hemisphere 
corresponding to the aura.
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Figure 2.3 Spreading suppression of cortical activation during migraine aura. 
(Adapted from Hadjikhani et al., 2001)
A- A drawing of progression of the visual aura affecting the left hemifield, over 
20 minutes.
B- MR signal changes (BOLD response) over time shown on the medial occipital 
cortex. Each time course represents a voxel in consecutive areas starting in the 
calcarine sulcus and progressing anteriorly.
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DWI/PWI
PWI abnormalities have been demonstrated in migraine with aura (Sanchez del Rio et 
al., 1999). During aura, relative cerebral blood flow was found to be decreased (27%) 
in the contralateral occipital cortex. rCBV was decreased (15%) and mean transit time 
increased (32%), persisting up to 2.5 hours into the headache phase. No changes in 
DWI have been observed in migraine with aura (Cutrer et al., 1998).
The level of blood flow reduction which occurs during aura is now clearer due to the 
advent of PET and MRI. Evidence from these imaging studies has demonstrated that 
ischaemia does not account for aura nor does it seem that significant ischaemia (>50% 
decrease in perfusion) is generally provoked by aura.
Migraine without aura 
SPECT
In contrast to migraine with aura, SPECT studies have failed to show any ictal 
changes in regional blood flow during migraine without aura. However, Sakai and 
Meyer reported a global blood flow increase during attacks (Sakai and Meyer, 1978).
PET
Bednarczyck studied nine subjects within 13 hours of onset of migraine without aura 
(Bednarczyk et al., 1998). They observed a 9.9% decrease in global CBF and a 5.2% 
decrease in CBV persisting for at least 6 hours. Oxygen metabolism and oxygen 
extraction remained unchanged.
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Woods et al reported a case report of a subject with migraine with no previous aura 
who unexpectedly developed a migraine during her participation in a visual activation 
paradigm whilst lying in a PET scanner (Woods et al., 1994). The subject described 
some visual blurring during one of the scans but did not clearly describe any other 
features of typical aura. The migraine was associated with bilateral hypoperfusion 
starting in the occipital lobes and spreading anteriorly into the temporal and parietal 
lobes. The contiguous spread covered areas in the territories of the posterior and 
middle cerebral artery.
Weiller at al investigated nine subjects with migraine without aura (Weiller et al.,
1995). The subjects presented with right-sided spontaneous headaches and were 
scanned within 6 hours of onset of migraine, prior to having taken any medication. 
They were scanned during spontaneous migraine attacks, following sumatriptan and 
inter-ictally. Interestingly, three of the subjects were on migraine preventives (P- 
blockers). The study revealed brainstem activation during the migraine which 
persisted after sumatriptan administration had relieved the pain. The resolution of the 
PET camera used was not high enough to identify specific nuclei but the foci of 
maximum increase were around the dorsal midbrain, which contains the dorsal raphe 
nucleus, and the dorsolateral pons, which contains the locus coeruleus. Activation was 
also seen in the anterior cingulate, visual and auditory association cortices. A case of a 
glyceryl trinitrate (GTN)-triggered migraine also revealed brainstem activation, on 
this occasion in the dorsolateral pons, which again persisted following abortion of the 
migraine (Bahra et al., 2001).
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(Weiller et al., 1995) (Bahra et al., 2001)
Figure 2.4 PET scans showing brainstem activation during migraine.
It is important to note that no such brainstem activation was noted in a PET study 
which evoked first division trigeminal pain by means of a subcutaneous injection of 
capsaicin into the forehead (May et al., 1998b), nor in imaging studies of cluster 
headache or SUNCT (May et al., 1998a; May et al., 1999). However, a recent PET 
study of hemicrania continua has demonstrated pontine activation (Matharu et al., 
2004b). This will be discussed later.
/M RI (BOLD)
There have been no fMRI studies exclusively involving migraineurs without aura. 
However, the studies described in the section above on “migraine with aura” included 
a mixed group of subjects with both migraine with and without aura.
PWI/DWI
No abnormalities have been recorded in either PWI or DWI in migraine without aura.
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Inter-ictal changes
In a SPECT study using Xenon and 99mTc HMPAO Friberg et al. reported inter-ictal 
cerebral blood flow asymmetries in almost 50% of migraineurs compared with 
controls (Friberg et al., 1994). The abnormalities occurred in an equal proportion of 
migraineurs with aura and those without aura. In a smaller SPECT study no such 
changes were noted (Lauritzen and Olesen, 1984). It was suggested that this may be 
because an equivalent regional analysis was not performed in this study. A number of 
other studies have also reported inter-ictal abnormalities (Lagreze et al., 1988; Levine 
et al., 1987; Schlake et al., 1990).
High resolution MRI was used to measure non-haem iron in the brainstem of 
seventeen subjects with episodic migraine (with and without aura) inter-ictally, 
seventeen controls and seventeen subjects with chronic migraine during headache 
(Welch et al., 2001). Both migraine groups exhibited increased levels of iron in the 
periaqueductal gray as compared to controls, with no significant difference between 
those with and those without aura.
Overall, there appears to be little evidence on the imaging front for a significant 
difference between the processes involved in migraine with and without aura except 
when the aura itself is studied.
Chronic migraine
MRI
As described above, the periaqueductal gray has been shown to exhibit abnormally 
high levels of iron in chronic migraineurs during headache (Welch et al., 2001). This 
appeared to be correlated with increased duration of migraine.
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PET
A PET study looking at eight chronic migraineurs who had bilateral suboccipital 
stimulators implanted demonstrated activation in the dorsal rostral pons which 
persisted when the stimulator was switched on to provide pain relief (Matharu et al., 
2004a). This is the same area which has been shown to be activated in episodic 
migraine (Bahra et al., 2001).
Triggered migraine with and without aura
A PET study by Anderson et al investigated attacks provoked by red wine in 11 
subjects with migraine with and without aura. They demonstrated reductions in 
regional cerebral blood flow (23%) and in oxygen metabolism (22.5%) in an area 
corresponding to the primary visual cortex. They did not detect any significant 
increases in blood flow during aura or headache.
2.2.2 Prolonged and persistent aura
The migraine aura, itself, has been examined, in detail, in a recent fMRI study 
(Hadjikhani et al., 2001) described above. These observations support the idea that 
CSD is responsible for aura. A sub-group of migraineurs, usually those with familial 
hemiplegic migraine or sporadic hemiplegic migraine, experience a prolonged or 
persistent form of aura. Prolonged aura was defined in the first IHS classification 
(Headache Classification Committee of the International Headache Society, 1988) as 
“aura symptoms lasting between one hour and one week”. Persistent aura is defined 
by the current IHS criteria (Headache Classification Committee of The International 
Headache Society, 2004) as “aura symptoms persisting for more than a week without 
radiographic evidence of infarction”. The functional deficit can take the form of 
visual, speech, cognitive, sensory and/or motor disturbance and occasionally altered
51
consciousness. The pathophysiology behind this form of migraine is not well 
understood. There are conflicting views as to whether this is a vascular or neuronal 
phenomenon.
There are a number of small studies, mainly case reports, in which such patients have 
undergone neuroimaging. The focus has been on detecting any evidence of 
ischaemia. DWI has, with the exception of two case reports, been normal (Gonzalez- 
Alegre and Tippin, 2003; Gutschalk et al., 2002; Iizuka T, 2004; Lindahl et al., 2002; 
Obemdorfer et al., 2004; Smith et al., 2002). In the two case reports there was 
evidence of decreased diffusion, three weeks into the aura, which affected the 
contralateral hemisphere (Butteriss et al., 2003; Chabriat et al., 2000). In both cases 
this eventually normalised. The abnormal diffusion was thought to reflect cerebral 
oedema rather than ischaemia. MRI with and without Gadolinium enhancement has 
been abnormal in some case reports, again suggesting oedema or inflammation of the 
affected hemisphere (Barbour et al., 2001; Butteriss et al., 2003; Crawford and 
Konkol, 1997; Iizuka T, 2004; Smith et al., 2002).
FDG-PET has been used to look at glucose metabolism and this was found to be 
reduced in two case reports (Gladstone JP, 2004; Gutschalk et al., 2002). Focussing 
on perfusion, PWI has mainly demonstrated unilateral hyperperfusion (Lindahl et al., 
2002; Obemdorfer et al., 2004; Smith et al., 2002) but was normal in one case study 
(Gutschalk et al., 2002). In a recent case report of persistent visual aura, however PWI 
demonstrated decreased perfusion in the relevant hemisphere which normalised when 
the symptoms resolved (Relja et al., 2005). Similarly, SPECT has also demonstrated 
unilateral hyperperfusion (Barbour et al., 2001; Gonzalez-Alegre and Tippin, 2003; 
Iizuka T, 2004; Iizuka, 2004; Obemdorfer et al., 2004). In all but one of these cases 
the hyperperfusion affected the hemisphere contralateral to the clinical signs.
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Magnetic Resonance Angiography (MRA) has been shown to be normal in two case 
reports (Barbour et al., 2001; Smith et al., 2002). There has only been one case report 
documenting angiographic evidence of narrowing of intracerebral vessels during an 
attack of prolonged aura but it must be noted that this case was somewhat atypical and 
involved a pregnant woman with evidence of thrombophilia whose attack was unlike 
her previous hemiplegic migraine attacks (Gonzalez-Alegre and Tippin, 2003). 
Overall, these studies do not suggest an ischaemic aetiology.
2.2.3 MRS studies in migraine
3Ip-m r s
11
The majority of MRS studies in migraine have used P-MRS in order to look for 
abnormalities in energy metabolism. Most of these involve inter-ictal scanning. 
Welch’s group were the first to apply MRS to migraine subjects (Welch et al., 1989). 
They studied a group of twenty migraineurs (eight migraineurs with aura and twelve 
migraineurs without aura) and twenty-seven healthy controls. Eleven migraineurs 
were studied during an attack (but not during aura) between 3 and 48 hours of 
headache onset. The remaining nine were studied inter-ictally. In the ictal group they 
observed a lower mean PCr/Pi and PCr/TP ratio and higher Pi/TP ratio as compared to 
the controls. When they further characterised the ictal group into migraine with and 
without aura they found that these observations were true for the migraine with aura 
group and not significant in the migraine without aura group. These abnormalities 
were more significant in anterior brain regions but also present in posterior region. 
Looking at the inter-ictal migraine group they found an increase in the mean Pi/TP 
ratio as compared to the controls.
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Analysis of intracellular pH revealed no significant differences between any of the 
groups.
Following on from these findings, an Italian group sought to examine both the brain 
and muscle of migraineurs to determine whether there was a generalised metabolic 
abnormality in migraine (Barbiroli et al., 1992; Barbiroli et al., 1990; Montagna et al., 
1994). They also examined what they termed “complicated forms of migraine” which 
included migraine with prolonged aura and migraine strokes. Their studies included 
fifteen subjects with “complicated” migraine, eighteen subjects with migraine with 
aura, twenty-two with migraine without aura and fifty controls. They examined the 
occipital region of the brain inter-ictally and also the gastrocnemius muscle. Overall, 
they observed lower PCr levels in all the migraine groups when compared with the 
controls (Montagna, 1995). The mean Pi was unchanged, calculated ADP and the rate 
of maximal ATP biosynthesis were significantly increased and phosphorylation 
potential significantly decreased in all migraine sub-groups. As for muscle, 
abnormalities were found when analysing recovery of PCr after exercise in twelve 
subjects with migraine without aura, thirteen with migraine with aura and all of the 
“complicated migraine” group.
Essentially the same findings have been described in a case report of migraine with 
prolonged aura (Sacquegna et al., 1992) and a familial hemiplegic migraine (FHM) 
family (Uncini et al., 1995). This family study was particularly interesting as it 
emerged that abnormalities were also present in two clinically asymptomatic members 
of the family.
Taking the results of all these studies it is evident that abnormalities in energy 
metabolism exist in migraineurs and these are not exclusive to brain tissue. Such 
abnormalities have been found inter-ictally and ictally. The possibility of
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mitochondrial dysfunction in migraine led to an open-label trial of Coenzyme Q, an 
essential element of the mitochondrial electron transport chain, as a migraine 
preventative (Rozen et al., 2002) and more recently a randomised controlled trial was 
conducted which demonstrated Coenzyme Q was superior to placebo (Sandor et al., 
2005).
Magnesium
MRS has also demonstrated significantly lower levels of magnesium in the occipital 
region of subjects with migraine when compared with controls (Boska et al., 2002; 
Lodi et al., 2001; Welch et al., 1989). The levels appear to be relatively lower in those 
with more severe clinical symptoms with subjects with hemiplegic migraine or 
complicated migraine aura having lower magnesium levels than those with migraine 
without aura. These studies were performed in the inter-ictal period but ictal 
abnormalities have also been reported with lower magnesium levels ictally when 
compared to controls (Ramadan et al., 1989).
'H-MRS
H-MRS has been used to look at lactate levels in migraine. Watanabe et al. looked at 
the occipital cortex inter-ictally in six subjects with migraine with aura and six 
controls (Watanabe et al., 1996). They found relatively higher levels of lactate in five 
patients who had experienced a migraine attack in the last two months. One 
migraineur had not had a migraine attack for four years. This subject did not 
demonstrate a lactate peak. The authors postulated a disturbance in aerobic oxidation 
which could arise from mitochondrial dysfunction (or ischaemia).
55
Other metabolite abnormalities have also been investigated. There has been one study 
examining eight subjects with migraine with aura inter-ictally and seven controls 
(Macri et al., 2003). Measurements of metabolite levels in the cerebellum revealed 
reduced choline values in the migraine group when compared with the control group. 
Choline is involved in the synthesis of membrane constituents and the 
neurotransmitter, acetylcholine. It must be noted, however, that the study is relatively 
small and the results may be affected by the short echo time as this can result in 
greater spectral overlap.
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2.3 Pain Processing and Functional Imaging
Functional imaging has been employed with the aim of elucidating the functional 
anatomy of pain pathways. Human pain is multi-dimensional, consisting of the 
sensory or discriminative components, the affective components and the cognitive 
components. The term “pain neuromatrix” has been proposed to explain the network 
of neural circuits involved in pain processing (Derbyshire, 2000). The human pain 
system is often divided into the lateral and medial pain systems. The medial pain 
system projects via the medial thalamic nuclei to prefrontal and anterior cingulate 
cortices, and parts of insular cortex. The lateral pain system projects via lateral 
thalamic nuclei to the primary and secondary somatosensory cortices (SI and SII, 
respectively) and the dorsal insula. The lateral pain system is thought to be 
responsible for the sensory-discriminative components of pain processing (the 
location, intensity and duration of the pain), the medial pain system is thought to be 
involved in the affective, motivational and evaluative components (Treede et al., 
1999).
Functional imaging has contributed significantly towards this knowledge of the pain 
processing systems. Many of the imaging studies used experimental models of pain 
since the study of spontaneous acute pain is obviously marred by practical difficulties 
such as getting the patient to the scanner in time. Studies have used tonic and phasic 
pain stimuli involving heat, cold, chemical and mechanical pain stimuli (Casey et al., 
1996; Derbyshire and Jones, 1998; Iadarola et al., 1998) and more recently laser 
stimuli which is thought to be superior since it allows activation in response to pain 
without the response to tactile stimulation (Bingel et al., 2002). Chronic pain 
syndromes have also been studied but these may involve a slightly different set of
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neural pathways than those involved in acute pain. PET and f-MRI are the main 
modalities used.
Although there are some disparities there are number of consistent findings from these 
studies which enable us to derive a reasonably good picture of pain neuroanatomy. I 
will focus on these consistent areas in the following section.
Anterior cingulate cortex (ACC)
This is one of the most consistently activated areas in pain studies (Ingvar, 1999). It is 
part of the medial pain system and is thought to be involved in the affective- 
evaluative dimension of pain. It is activated in acute pain, visceral pain and appears to 
be tonically activated in chronic pain states (Hsieh et al., 1995). In one study right 
anterior cingulate activation has been reported irrespective of the side of pain (Hsieh 
et al., 1995). However, this finding has not been replicated (Bingel et al., 2003; Bingel 
et al., 2002; Coghill et al., 1994).
In a study using hypnotic suggestion to alleviate the unpleasantness associated with 
noxious stimuli without altering the intensity of pain it was found that the activation 
in the ACC was reduced whereas the activation in the somatosensory cortex remained 
unchanged (Rainville et al., 1997). Similarly, the ACC was also activated in a study 
producing the illusion of pain when in fact the stimuli were not noxious (Craig et al.,
1996).
Clinical evidence for the function of the ACC is provided by observations of chronic 
pain patients. Following cingulotomy (surgery to cut the white matter tract underlying 
the ACC) these patients remained aware of the pain but it no longer bothered them 
(Santo et al., 1990).
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Somatosensory cortex
The primary somatosensory cortex (SI) is involved in the spatially discriminatory 
aspects of pain stimuli. It is only found to activated in 50% of imaging studies in pain 
(Peyron et al., 2000) and is activated bilaterally with greater activation contralaterally 
to the site of painful stimulus (Youell et al., 2004). The secondary somatosensory 
cortex (SII) is more consistently activated. However, there is a paucity of nociceptive 
neurons in this region and poorly demarcated receptive fields and activations are 
generally bilateral (Ingvar, 1999). These observations suggest that it is less likely to 
be involved in spatial discrimination. It has been proposed that SII may be involved in 
recognition, learning and memory of painful events (Schnitzler and Ploner, 2000).
Insula
The insula is fairly consistently activated in pain studies and, in fact, the insula cortex 
is the only cortex where stimulation has elicited pain (Ostrowsky et al., 2002). It can 
be functionally divided into an anterior part, which is the region activated in most pain 
studies, and a posterior part which can sometimes be difficult to distinguish clearly 
from the SII cortex. The anterior insula is thought to be involved in the autonomic and 
affective components of pain. It is also proposed that the insula is involved in 
intensity coding (Coghill et al., 1999; Peyron et al., 1999). Activation is often bilateral 
but a recent study looking at hemispheric lateralisation has found that the left side 
demonstrates greater activation independent of stimulus side suggesting this region is 
also involved in sensory-discriminative aspects of pain (Youell et al., 2004). There is 
some suggestion that posterior insula activation is predominantly contralateral 
(Brooks et al., 2002).
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Thalamus
The thalamus, despite its role as a relay centre for afferent input into the brain, is less 
consistently activated in experimental pain studies. It can be divided into medial and 
lateral parts. The medial thalamus receives input from the ascending pathways from 
the spinal cord and reticular formation and projects diffusely to the cortex forming 
part of the medial pain system. The lateral thalamus, including the ventrobasal 
thalamus, is somatotopically organised and receives input from the ascending tracts 
and sends fibres to the somatosensory cortex. It forms part of the lateral pain system. 
The thalamus is bilaterally activated in some studies (Casey et al., 1996; Derbyshire et 
al., 1998) which suggests that the activation is not merely a sensory response. The 
bilateral response is thought to reflect activation of the medial nuclei with the lateral 
nuclei being activated contralaterally (Bingel et al., 2003). It is likely to be involved in 
both discriminative and attentional networks of pain. The inconsistency of activation 
in studies may be due to methodological issues of sensitivity.
Prefrontal cortex
The dorsolateral prefrontal cortex has often been shown to be activated in pain 
studies. It is thought to be involved in the cognitive dimension of pain. In a recent 
fMRI study it was demonstrated that placebo analgesia was associated with increased 
activity during the anticipation of pain in the prefrontal cortex (Wager et al., 2004).
Other areas of activation which are less consistent in pain imaging studies include the 
cerebellum, midbrain, hypothalamus and basal ganglia (caudate and lenticular nuclei).
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Chapter 3. Laterality of migraine headache
Unilateral pain has been a hallmark of migraine since Galen (AD 131-201) introduced 
the term Hemicrania to describe the disorder (Lance and Goadsby, 1998a). Laterality 
of activation in functional imaging studies of general pain has been discussed, to some 
extent, in the previous chapter. However, as far as we are aware there have been no 
imaging studies specifically designed to explore the issue of laterality in migraine. A 
PET study of GTN-triggered cluster headache involving nine subjects, five with left­
sided and four with right-sided attacks, demonstrated bilateral insula activation, 
contralateral thalamic and anterior cingulate activation with ipsilateral hypothalamic 
activation (May et al., 1998a). It must be noted, however, that this study was not 
designed to look at laterality and so left-sided and right-sided groups were not 
analysed separately. An MRI study that detected increased iron levels in the 
periaqueductal gray (PAG) region of migraineurs did not find any side-to-side 
differences in PAG iron and therefore could not be used to make any inferences about 
laterality (Welch et al., 2001). The study reporting PAG-stimulating electrodes 
triggering migraine referred to patients implanted bilaterally with no previous 
headache history, so laterality was not discernible (Raskin et al., 1987). In a further 
series of sixty-four patients in whom electrodes were implanted unilaterally, fifteen 
reported post-implantation headache and accompanying symptoms, such as 
lacrimation, visual blurring and nasal congestion, that were exclusive to, or worse on 
the ipsilateral side (Veloso et al., 1998).There are three case reports of new onset 
migraine following haemorrhage. Following a brainstem (pontine) cavernous angioma 
ipsilateral migraine was reported (Afridi and Goadsby, 2003), whereas contralateral 
migraine was reported following a dorsal midbrain bleed (Goadsby, 2002) and in a 
further case report of a pontine cavemoma (Katsarava et al., 2003a).
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Autonomic asymmetry has been reported in migraine. One study measured 
electrodermal responses to visual and auditory stimuli inter-ictally in unilateral 
migraineurs and found that left-sided pain was associated with under-responsiveness 
and fast habituation whereas right-sided pain was associated with over-responsiveness 
and slow habituation of this sympathetic response (Gruzelier et al., 1987). A recent 
study reported parasympathetic but no sympathetic asymmetry in unilateral 
migraineurs with left-sided migraineurs displaying a greater parasympathetic response 
to an aversive stimulus (Avnon et al., 2004).
Electrophysiology also provides some data regarding laterality. Kaube et al found 
facilitation of the nociception-specific blink reflex response predominated on the 
headache side only during migraine (Kaube et al., 2002).
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Chapter 4. Glyceryl trinitrate (GTN): a human migraine model
The unpredictable and episodic nature of migraine introduces practical difficulties in 
research in this field, especially in imaging studies as well as therapeutic intervention 
studies. The difficulties include getting patients to travel to the research centre whilst 
suffering with severe pain or nausea and vomiting from migraine. This delays the 
onset of any therapy in interventional studies and introduces a selection bias in that 
those most debilitated will not participate in the study as they are unable to travel. It 
also means that the attack cannot be followed from the very onset. Also, the 
pathophysiology and clinical manifestations of the headache may change throughout 
the attack. For example, in migraine there may be a premonitory phase prior to the 
headache or aura phase. Developing approaches to triggering migraine reliably is 
important for advancing understanding of the disorder. An effective migraine model 
will enable the headache to be followed in a controlled environment throughout the 
attack. The model needs to be reliable, reproducible and validated.
Glyceryl trinitrate (GTN) or nitroglycerine was recognised to trigger very typical 
headaches in munitions workers (Laws, 1898), and these effects were described in 
detail some years later (Rabinowitch, 1944). Dalsgaard-Nielsen (1955) suggested 
GTN administration may be a test for headache classification and certainly migraine­
like headache developing following sub-lingual GTN is well recognised (Sicuteri et 
al., 1987). The method has been refined by the Copenhagen Group (Iversen, 2001; 
Iversen, 1992; Iversen and Olesen, 1994; Iversen et al., 1989). They conducted a 
blinded study of controls and subjects with migraine without aura and monitored 
responses to increasing doses of intravenous GTN (Olesen et al., 1993). They 
demonstrated a dose-dependent headache response with a ceiling effect and maximum 
headache score at O.Spg/kgWn of GTN. The migraineurs reported initial, immediate
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headaches of greater intensity than the controls and many experienced a second 
delayed headache which was labelled as a typical migraine. There was no such 
delayed headache in the controls. It was subsequently reported that migraine headache 
could also be triggered in some subjects with migraine with aura although the aura 
was not triggered (Christiansen et al., 1999).
Sances and colleagues (2004) have recently published a study involving 197 
migraineurs on the reliability of the nitroglycerin trigger in migraine and cluster 
headache using sublingual GTN. They determined that the sensitivity and specificity 
of the test in migraine without aura was 82.1% and 96.2% respectively. In migraine 
with aura the test was less sensitive (13.6%) but the specificity was the same. 
Interestingly, migraine aura was triggered in three of twenty-two subjects in the 
migraine with aura group. A further six subjects developed migrainous headache 
without aura similar to those in the study by Olesen’s group (Christiansen et al.,
1999).
GTN is highly lipophilic and easily crosses the blood-brain barrier. It is thought to 
induce migraine through a nitric oxide (NO) mediated process. The long- acting 
nitrate 5-isosorbide mononitrate induces a dose-dependent headache but its 
metabolites, apart from NO, are different from those of GTN (Iversen et al., 1992). N- 
acetylcysteine, which augments the effects of GTN in the heart by increasing the 
formation of or enhancing the effect of NO, also augments the headache response to 
GTN (Iversen, 1992). NO is a molecule which is ubiquitous throughout the brain. It 
has numerous physiological functions including neurotransmission, regulation of 
cerebral blood flow, sensory processing, pain perception and long-term potentiation. 
Endogenous NO is generated by the conversion of arginine to citrulline by nitric oxide 
synthases of which there are at least three types. Two are constitutive and
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calcium/calmodulin dependent: endothelial NOS (eNOS) and neuronal NOS (nNOS) 
and the third is inducible and calcium/calmodulin independent: inducible NOS 
(iNOS). The latter produces larger quantities of NO once expressed.
The role o f nitric oxide in migraine
There is now extensive evidence for the role of nitric oxide in migraine both from 
human and animal studies (Thomsen and Olesen, 2001). Human studies have shown 
abnormalities in metabolites of nitric oxide. The physiological actions of NO are 
mainly mediated by activation of guanylate cyclase and a consequent increase in 
cyclic guanosine monophosphate (cGMP). Serum cGMP and nitrites have been shown 
to be raised during migraine (Sarchielli et al., 2000; Stepien and Chalimoniuk, 1998). 
Platelet levels of nitrate, nitrite and cGMP are also higher during a migraine attack as 
compared with outside an attack or in healthy controls and they decrease inter-ictally 
following treatment with propranolol (Shimomura et al., 1999). As described above, 
clinical studies have demonstrated that a nitric oxide donor such as glyceryl trinitrate 
can trigger migraine. In a double-blinded study it was demonstrated that the NO 
synthase inhibitor L-N methylarginine (L-NMMA) hydrochloride was effective in the 
acute treatment of migraine (Lassen et al., 1998). This suggests an ongoing role for 
NO in mediating the migraine, not only as an initiator. Furthermore, there is some 
evidence from an open-label study that the NO-scavenger, hydroxycobalamin has an 
effect on migraine prophylaxis (van der Kuy et al., 2002). GTN-induced migraine has 
also been shown to respond to sumatriptan (Afridi et al., 2004; Iversen et al., 1996).
In migraineurs, GTN caused a decrease in the velocity of middle cerebral artery flow 
during infusion indicating a dilatation of the artery which reversed after the end of the 
infusion (Thomsen et al., 1994). It has, therefore, been suggested that vasodilatation
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of cerebral vessels may be partly responsible for the triggering mechanism of nitric 
oxide. However, there is evidence to suggest that this is not the case. In a recent study 
sildenafil was found to induce migraine with a similar time course and success rate to 
GTN (Kruuse et al., 2003). Sildenafil is a phosphodiesterase 5 inhibitor and 
consequently is involved in cGMP metabolism. Interestingly, it was not found to 
produce any significant changes in the middle cerebral artery diameter of the subjects 
suggesting that vasodilatation of large cerebral vessels is not necessary in order for 
migraine to develop (Kruuse et al., 2003). However, the immediate GTN-induced 
headache is thought to be related to vasodilatation and an equivalent headache was not 
seen following sildenafil.
It is unclear how nitric-oxide, with its short half-life of less than 30 seconds, can 
trigger a delayed migraine. One possibility is that NO induces neurogenic 
inflammation. Exogenous NO may also induce endogenous NO production as well as 
the production of other inflammatory mediators. iNOS may be responsible for the 
triggered endogenous production. Reuter et al found dose-dependent iNOS mRNA 
upregulation in rat dura beginning 2 hours after GTN infusion (Reuter et al., 2001). 
Also, in a placebo controlled study 150mg prednisone was found to reduce the 
delayed headache induced by GTN in a group of migraineurs (Olesen). It is known 
that prednisolone inhibits iNOS. It has recently been shown that plasma levels of 
citrulline, a marker for endogenous NO production, are increased 60 minutes 
following GTN infusion in patients with IHS defined chronic tension-type headache 
when compared to healthy controls although this has not yet been demonstrated in 
migraine (Ashina et al., 2004).
During migraine blood levels of calcitonin gene related peptide (CGRP) are elevated 
in the external jugular vein (Goadsby et al., 1990). It has been shown that CGRP can
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also induce migraine (Lassen et al., 2002). It is possible that CGRP could be the 
mediator through which nitric oxide induces migraine as GTN has been shown to 
liberate CGRP from pial arterioles and other vascular beds (Booth et al., 2000; Wei et 
al., 1992) and raised levels of CGRP are found in GTN triggered migraine (Juhasz et 
al., 2003). Allodynia has been demonstrated in humans during migraine (Burstein et 
al., 2000). This is thought to be the result of central sensitisation. Nitric oxide has 
been shown to be involved in central sensitisation in the spinal cord (Lin et al., 1999; 
Wu et al., 2001) and to induce hyperalgesia in animals (McMahon et al., 1993; Meller 
and Gebhart, 1993). The role of NO in central pain modulation has been demonstrated 
by intra-RVM injection of a NO donor which led to a dose-dependent facilitation of 
the tail-flick reflex in rats (Urban et al., 1999). Conversely, injection of the NOS 
inhibitor, L-NAME, attenuated mustard-oil induced hyperalgesia. Subcutaneous GTN 
has been found to produce a significant increase of nNOS and Fos protein-like 
immunoreactivity in the trigeminal nucleus caudalis (Pardutz et al., 2000) and 
brainstem nuclei (Tassorelli and Joseph, 1995) in rats. Administration of the NOS 
inhibitor L-NAME reduced Fos protein-like expression in the trigeminocervical 
complex of the cat (Hoskin et al., 1999).
Animal studies have also revealed that cortical spreading depression, which is thought 
to be responsible for migraine aura in humans, elicits widespread release of NO and 
increased cortical concentrations of cGMP (Read et al., 2001). The CSD induced 
increase in cortical NO is reduced when sumatriptan is given as a pre-treatment in cats 
and rats (Read and Parsons, 2000).
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PART II. METHODS
Chapter 5. PET data acquisition and analysis
The theoretical basis of PET and SPM is discussed in chapter 2. In this chapter, the 
practical aspects will be described.
5.1. PET
PET scans were performed with an ECAT EXACT HR+ scanning system (CTI 
Siemens, Knoxsville, TN) in three-dimensional mode with septa retracted. Images 
were reconstructed by filtered back-projection into 63 image planes (separation 2.4 
mm) and into a 128 x 128 pixel image matrix (pixel size 2.1 x 2.1 mm2). The resultant 
nominal resolution was 6.4 ± 0.2 mm.
The subject’s head was placed in the tomogram using a supportive moulding to 
minimize movement. Markings were made on the face to check for movement in 
between scans. The subject was asked to lie still with their eyes closed during the 
scans. The lights in scanning area were dimmed. A transmission scan was performed 
to ensure the positioning was correct and to allow for attenuation correction. An 
antecubital vein cannula was used to administer the tracer, 350 mBq of H2150. The 
activity was infused into subjects over 20 seconds at a rate of 10 ml/min. The data 
were acquired in one 90-second frame beginning 5 seconds before the peak of the 
head curve. The interval between scans was 8 minutes. A maximum of 12 scans per 
subject was obtained. After reconstruction the dynamic images were transferred to a 
SPARC SUN system workstation for preprocessing and analysis.
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5.2. SPM
Image Kernel
1
Realignment —► Smoothing
Normalisation
General linear model
P  < 0.001
Template
Statistical
inference
Fig 5.1 Statistical analysis using SPM.
The raw data undergo preprocessing prior to the statistical analysis. This occurs in 
three stages:
1) Realignment and coregistration-this involves correction for head movement 
between each scan. Each of the images is realigned and coregistered with reference to 
the first scan.
2) Spatial normalisation- this involves warping the image to fit it to a standardised 
normal brain template, usually the Talairach and Toumoux brain (Talairach and 
Toumoux, 1988) or the Montreal Neurological Institute (MNI) brain. Normalisation 
allows intersubject comparisons to be made.
D esign  matrix Statist ical parametric map (SPM )
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3) Smoothing- this is a process by which data points are averaged with their 
neighbours in a series. This has the effect of blurring the sharp edges in the smoothed 
data. The data are convolved with a Gaussian kernel. This enables the use of the 
Gaussian field theory to allow statistical inferences to be made about regionally 
specific effects. Smoothing also improves the signal-to-noise ratio and it enables 
averaging across subjects. It improves the probability of finding commonalities 
between patients. The data in our studies was smoothed with a Gaussian filter of 
10mm full width at half maximum.
Following the preprocessing the data are incorporated into a design matrix (Figure 
2.2) using the general linear model and statistical parametric maps are derived using 
pre-specified contrasts.
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PART III. CLINICAL STUDIES
Chapter 6. Exploring GTN triggering of migraine
Introduction
Migraine is characteristically episodic making it challenging to perform clinical 
studies. There is no recognised model of migraine in animals that encompasses the 
syndrome completely (Edvinsson, 1999), so a reliable experimental human model of 
migraine is an important goal for those interested in research in this field that can be 
difficult to achieve (Levy et al., 2003). The GTN model has the potential to be used in 
this manner (see Chapter 4).
There is some debate as to whether triggered attacks are in fact genuine migraine 
attacks identical to spontaneous migraine attacks. This issue is crucial to any use of 
the model for predicting effects in so-called spontaneous migraine. We set out to 
examine the reproducibility of the model, also an essential feature for some 
experimental clinical studies, and to document carefully the clinical features of the 
period from trigger administration to headache onset. We sought to extend previous 
studies of the premonitory phase of migraine (Giffin et al., 2003) and specifically 
determine if such symptoms occurred in GTN-triggered migraine.
Methods
Patients with migraine without aura (n = 23) and migraine with aura (n = 21), and 12 
healthy controls were recruited as part of a functional imaging study in glyceryl 
trinitrate-triggered migraine (Table 6.1). The migraineurs suffered from attacks 
fulfilling International Headache Society criteria for migraine with and without aura 
(Headache Classification Committee of The International Headache Society, 2004).
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They were not taking any preventive medication and the attack frequency was less 
than 15 days per month with a minimum of one attack per month. Pregnant women 
were excluded and a pregnancy test was performed in women of child-bearing age. 
Details of their usual migraine attacks were noted included premonitory symptoms.
Healthy volunteers were recruited as controls on the basis of no personal or family 
history of migraine or migrainous headaches and no history of frequent tension-type 
headaches. They were excluded if they were on any regular medication.
Glyceryl trinitrate (GTN) administration
Each subject received an intravenous infusion of 0.5 pg/kg/min GTN over twenty 
minutes via a cannula inserted into the right antecubital vein. This dose has been 
successfully used by others (Olesen et al., 1993).The migraineurs were all headache 
free for at least 48 hours prior to the initiation of the infusion. Headache intensity and 
characteristics were recorded every 5 minutes during the infusion and thereafter every 
15 minutes. Subjects were asked to describe any head pain or other associated 
symptoms such as nausea, photophobia, phonophobia, worsening of pain on head 
movement. In addition they rated the severity of any headache on a verbal rating scale 
of 0-10 and the location and nature of the headache was noted. Blood pressure and 
pulse were monitored during the infusion. Subjects were monitored for up to four 
hours after the infusion and periodically asked to describe any headache. They were 
also questioned about premonitory symptoms such as yawning, fatigue, neck stiffness, 
thirst, urinary frequency, cravings or mood change (Giffin et al., 2003). In the 
migraine subjects whose attacks were successfully triggered subcutaneous 
sumatriptan 6mg s/c was then administered to abort the attack and time taken until
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relief was noted. Non-responders, migraineurs who did not develop a migraine, 
received a follow-up telephone call the next day to document any possible delayed 
headache.
Repeat administration o f GTN
Subjects whose attacks were successfully triggered, and the control group, were 
invited back for a repeat session at least a week later in order to scan them for a 
functional imaging study. Clinical data were again recorded during the second 
session. The controls were only studied in the imaging session.
Results
Controls
Three of the controls developed a headache during the infusion which did not subside 
after the infusion finished. The headaches persisted for at least two and a half hours 
and the subjects were then excluded as controls. The clinical features of the attack are 
documented in Table 6.2. One of these patients was adopted and so a family history of 
migraine could not be excluded. The second later admitted that she thought her 
brother has migraines although a family history of migraine was initially denied at the 
screening stage. The third patient did suffer from featureless headaches approximately 
two or three times a year. Of the remaining eight controls six experienced a mild, 
generalised headache during the infusion which then faded within 20 minutes of the 
end of the infusion. Two experienced no headache at all but described an odd 
sensation in their head during the infusion.
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Headache
Session one: A migraine attack was successfully triggered in thirty-three out of the 
forty-four migraineurs (75%). The trigger rate was 83 percent for migraine without 
aura and 67 percent for migraine with aura (x =1.49, P =0.22). Four subjects 
withdrew from the study after the first session.
Session two: In twenty-eight out of the twenty-nine of those remaining a migraine was 
successfully re-triggered during the second session. Interestingly, in the subject in 
whom the migrainous headache was not triggered the second time, a visual aura 
without headache was triggered 70 minutes after the start of the infusion. This took 
the form of a zig-zag pattern across the visual field, blurring of vision and alteration 
of colours. This lasted 20 minutes and was not followed by a headache. His previous 
attacks typically involved a bilateral headache with nausea, photophobia and 
phonophobia. He very rarely had visual aura.
Migraine with aura
Visual aura was triggered in another subject with migraine with aura. In this case he 
had both his typical visual aura and migrainous headache and both were successfully 
reproduced during the second session with similar latencies of onset, 150 minutes and 
160 minutes, respectively, after GTN.
Latency o f migraine
The latency of onset of the migraine was determined as the time taken from onset of 
the infusion to the development of a migraine which fulfilled International Headache
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Society criteria for migraine and was typical for the subject. There was no significant 
difference in latency of onset of migraine during the first and second triggering 
sessions (Wilcoxon Signed Ranks test Z = 0.55, P = 0.58). The mean latency for the 
first session was 142 minutes and for the second session 140 minutes (range 20-330 
minutes). Fifty percent of attacks were triggered between 90 and 180 minutes.
Laterality o f triggered attacks
The laterality of the headache (i.e. left /right-sided /bilateral) was reproduced in all but 
two out of thirty. The first subject had right sided migrainous headaches more 
frequently than left-sided. During the first session a left-sided headache was triggered 
but during the second session she developed a right-sided headache. The second 
subject who usually has left sided headache developed bilateral headache during the 
first session but then reverted back to his usual left-sided headache during the second 
session.
Premonitory Symptoms
Fifteen of the thirty-three migraineurs described premonitory symptoms with their 
usual spontaneous attacks. Symptoms included yawning, tiredness, irritability, neck 
stiffness, frequency of urination, hunger and low mood. Twelve of these described 
some of these symptoms after the GTN infusion but prior to the onset of the triggered 
migraine (Table 6.3). The premonitory symptoms were highly reproducible as was the 
latency of onset from start of infusion with a mean latency of 53 minutes in session 
one and 59 minutes in session two from a range of 15-120 minutes. (The data
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regarding latency of onset were available for 8 of the 12 subjects with triggered 
premonitory symptoms).
Non-responders versus responders
There was a trend towards a greater proportion of subjects with migraine with aura 
being in the non-responder group but this was not statistically significant (x2 =1.49, P 
= 0.22; Table 6.4).
Effect o f sumatriptan
Sumatriptan 6mg s/c was administered to 59 patients who had been successfully 
triggered, 32 in session one and 27 in session two. 83% of patients had mild or no 
headache at 2 hours post treatment. The median time to relief was 30 minutes in 
session one and 35 minutes in session two. The effect was highly reproducible with all 
subjects who responded in session one also responding in session two.
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Table 6.1 Subject characteristics.
Group Migraine without 
aura 
n = 23
Migraine with aura 
n = 21
Controls 
n — 11
Successful induction of 19/23 14/21
migraine (83%) (67%)
Female/Male 11:12 17:4 4:7
Mean age 46 44 38
(age range) (25-68) (27-65) (21-58)
Mean Frequency of 3 3
attacks/month (range) (1-8) (1-12)
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Table 6.2 Glyceryl trinitrate (GTN) triggered headache in controls.
Subject
Triggered delayed headache
Time
(hours) Pain Severity
Worse with 
movement Nausea Photophobia Phonophobia
1 Onset
during
infusion
Dull ache centred 
around vertex, 
worse on 
movement
2/10 + - - -
2
Onset
during
infusion
Wave of pain 
around vertex
1/10 - - - -
3
Onset
during
infusion
General 
“muzziness” in 
whole head
1/10 - - - -
Table 6.3 Premonitory symptoms in glyceryl trinitrate triggered migraine.
Subject Premonitory symptoms 
in spontaneous attacks
Premonitory symptoms 
during session 1
Premonitory symptoms 
during session 2
1 Neck stiffness, tired - -
2 Neck stiffness, yawning Neck stiffness Neck stiffness
3 Excessively tired, irritable Excessively tired Excessively tired
4 Tired, yawning, neck 
stiffness
Neck stiffness, tired Tired, yawning
5 Yawning, irritable, 
detached
Yawning Yawning
6 Yawning, tiredness Yawning, tiredness Yawning, tiredness
7 Yawning, hunger, neck 
stiffness, belching
Neck stiffness Neck stiffness
8 Frequency of urination, 
neck stiffness
Frequency of urination, 
neck stiffness
Frequency of urination, 
neck stiffness
9 Frequency of urination, 
hunger cravings
10 Thirst - -
11 Yawning, tired, neck 
stiffness
Yawning, tired Yawning, tired
12 Yawning Yawning Yawning
13 Low mood, tired Tired Tired
14 Yawning, tired Yawning, tired Yawning, tired
15 Yawning, hunger craving Yawning Yawning
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Table 6.4 Comparison of responders and non-responders to glyceryl trinitrate 
triggered migraine.
Group Non-responders 
n = 11
Responders 
>7 = 33
MWA:MO 7:4 14:19
Female/Male 8:3 27:16
Mean Age 43 45
Mean Frequency of 
attacks/month
2.3 3
Abbreviations'.
MO, migraine without aura 
MW A, migraine with aura
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Migraine with aura 
Migraine without aura 
Controls
Subjects [%]
Responder Non-Responder
Figure 6.1 Response to GTN trigger amongst different groups.
81
Discussion
The current study confirms previous work that has established GTN as a potent trigger 
for migraine with three-quarters of the migraineurs responding. The study 
characterises the reproducibility of the method, which must be considered excellent: 
almost all patients have a second attack that is at the same time and with the same 
clinical features. Moreover, the characteristics of the GTN-triggered versus 
spontaneous attacks are remarkably similar, including the common experience of 
premonitory symptoms. The data further confirm that this model has much to offer the 
study of migraine, and support a view that the attacks triggered are, in essence, no 
different than spontaneously occurring attacks.
Previous studies, which include those done by Olesen’s group, have had a similar 
success rate in triggering migraine with GTN (Iversen, 2001). Our study involved 
larger numbers of migraineurs and subjects were triggered on two separate occasions. 
The latency of development of migraine appeared to be shorter in our study: mean 
141 minutes compared to previous reports where the peak intensity was at 236 
(Christiansen et al., 2000) or 330 minutes (Thomsen et al., 1994). For ethical reasons 
we did not let the headache intensity increase to the maximal level and so abortive 
medication was administered reasonably soon. Another reason for the difference may 
be due to the fact that in the two previously reported studies (Olesen et al., 1993; 
Thomsen et al., 1994) patients were observed for one hour and three hours 
respectively following the start of the infusion whereas we monitored the patients for 
four and a half hours following the start of the infusion. This would mean that they 
would have to rely on the questionnaire filled in by the patient at home in order to
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determine onset of the migraine whereas in our subjects the migraine developed 
whilst they were being monitored. Also, in our study they were in a quiet, comfortable 
environment without distractions and were continuously having to focus on their 
headache. Sances and colleagues (Sances et al., 2004) have recently published a study 
on the nitroglycerin trigger in migraine and cluster headache involving 197 
migraineurs using sublingual GTN. Their findings on latency of onset were similar to 
those reported here: 135 minutes and 141 minutes, respectively. Their success rate of 
induction was also very similar with an overall rate of 77% (82.1% for migraine 
without aura group and 40.9% for migraine with aura).
Aura
Visual aura was triggered in two of the subjects with migraine with aura. One of these 
subjects was the only one in whom we were unable to trigger the headache the second 
time. He had recently recovered from an upper respiratory tract infection on the first 
occasion which may help to explain why he was more susceptible to a typical 
migraine following the GTN trigger. The other subject always had visual aura 
preceding his migrainous headache. On both occasions a visual aura was triggered 
following the GTN infusion (150 minutes and 160 minutes, respectively) followed by 
a headache. We did not expect this finding. In the study by Olesen’s group involving a 
GTN infusion in 12 patients with migraine with aura (Christiansen et al., 1999) six of 
them developed migrainous headaches but none developed aura. There had been a 
case report of new onset migraine with aura in a 46 year old following sublingual 
GTN for angina (Bank, 2001) but these episodes only occurred following GTN and 
the patient apparently had no previous history of migraine. However, in the recently 
published study by Sances and colleagues (Sances et al., 2004) migraine aura was
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triggered in three of twenty-two subjects in the migraine with aura group. A further 
six subjects developed migrainous headache without aura similar to those in Olesen’s 
study. The triggering of the aura in our subject may have occurred by chance 
however, the fact that it was reproducible makes this less likely, so perhaps the 
triggering of aura is rarer but possible.
Premonitory symptoms
Premonitory symptoms precede the headache in migraine. In a recent study (Giffin et 
al., 2003) 120 migraineurs were given an electronic diary to record non-headache 
symptoms. The most common premonitory symptoms were feeling tired and weary 
(72% of attacks with warning features), difficulty concentrating (51%), and a stiff 
neck (50%). Many of these symptoms were also described by our patients during both 
induction sessions. To our knowledge there has not been any previous documentation 
of premonitory symptoms following GTN triggering. The finding is important as it 
implies that the migraine process is triggered from the earliest point. It also suggests 
that after the trigger the neurological processes that follow are identical to those which 
occur in spontaneous migraine attacks.
Conclusion
To conclude, we have provided further evidence of the reliability and validity of the 
GTN model in triggering migraine. The presence of premonitory symptoms extends
84
the clinical phenotype of the attacks further establishing them as the same as 
spontaneous migraine. Furthermore the reproducibility in terms of phenotype of 
attack, laterality and timing should provide considerable confidence in results from 
the model both in terms of understanding migraine mechanisms and studying its 
treatment.
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Chapter 7. A PET study in spontaneous migraine
Introduction
One of the most significant studies in migraine neuroimaging was that of Weiller and 
colleagues (Weiller et al., 1995). The study, as described in chapter 2, involved nine 
subjects with migraine without aura who were scanned during spontaneous migraine 
attacks and following sumatriptan. Interestingly, three of the subjects were on 
migraine prophylactics (P-blockers). The study revealed brainstem activation during 
the migraine that persisted after sumatriptan administration had relieved the pain. The 
resolution of the PET camera used was not high enough to identify specific nuclei but 
the foci of maximum increase were around the dorsal midbrain and dorsolateral pons. 
It has been difficult to replicate these findings because of the practical logistic 
limitations of imaging spontaneous migraine, with only a single GTN-triggered case 
thus far in the literature (Bahra et al., 2001). Indeed when acute migraine has been 
studied using MRI methods, such as perfusion weighted (Cutrer et al., 1998; Sanchez 
del Rio et al., 1999) or BOLD f-MRI (Cao et al., 1999; Hadjikhani et al., 2001; Welch 
et al., 1998), the focus has been on patients with migraine with aura or on cortical 
changes in patients without aura. These studies have produced fascinating results, 
although they were not primarily aimed at further exploring the issue of brainstem 
involvement in migraine.
One aim of this study was to replicate and perhaps refine published findings taking 
advantage of the advances in PET scanning and analysis methods.
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Methods
Patients
We recruited six subjects, three with migraine with aura and three with migraine 
without aura as defined by the International Headache Society diagnostic criteria 
(Headache Classification Committee of The International Headache Society, 2004).
All the subjects were female with an age range of 30-55 (Table 7.1). They had a 
migraine frequency of between one and four per month. One subject was withdrawn 
from the study as it emerged that she was taking pizotifen. None of the remaining 
subjects were on any migraine preventives or other medications.
The subjects were scanned within 24 hours of onset of migraine and prior to any 
abortive medication. No abortive medications had been taken within the preceding 48 
hours. The subjects were offered sumatriptan treatment following the scans. Post­
treatment scans were not incorporated into the study design. Pain free scans were 
taken at least 72 hours after a migraine headache. The order of scanning was 
randomised (ictal versus inter-ictal).
PET data acquisition and analysis
An antecubital vein cannula was used to administer the tracer, ~350 mBq of H2150. 
The activity was infused into subjects over 20 seconds at a rate of 10 ml/min. The data 
were acquired in one 90 second frame beginning 5 seconds before the peak of the head 
curve. The interval between scans was 8 minutes. Each session involved four scans. 
Attenuation correction was performed with a transmission scan acquired at the 
beginning of each study.
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SPM99 (Wellcome Department of Imaging Neuroscience,
http://www.fil.ion.ucl.ac.uk/spm) was used for data analysis. Images were realigned 
with the first as the reference and then co-registered and spatially normalised into the 
space defined by the atlas of Talairach and Toumoux (Talairach and Tournoux, 1988). 
The normalised images were smoothed with a Gaussian filter of 10 mm full width at 
half-maximum since increasing the smoothness of the data increases the sensitivity of 
the analysis in a monotonic fashion (Friston et al., 1996). Statistical parametric maps 
were derived with pre-specified contrasts, comparing regional cerebral blood flow 
during headache versus rest. An uncorrected threshold of P < 0.001 was chosen for 
tabular and graphical reporting. However, our results survived a small volume 
correction using a 12 mm radius sphere at P < 0.05 centred on the brainstem maxima 
as reported (Bahra et al., 2001). There were three right-sided and two left-sided 
attacks. The analysis included data from all five subjects. Analysis was performed 
both with and without taking symptomatic lateralisation into account. The first 
analysis discounted the side of the attack. In the second analysis the scans of subjects 
with left-sided attacks were reflected across the midline for a “flipped” analysis 
(Friston, 2003). This was then analysed in a multi-group analysis along with a 
spatially transposed version of this second group using a fixed effects model. This 
enabled us to detect responses which lateralise in relation to symptoms. Our statistical 
model included the main effect of migraine (present versus absent), time (scans 1 
through 4) and the migraine by time interaction. This general linear model conforms 
to an ANOVA (Friston et al., 1995).
Results
Two of the patients had a typical migrainous aura prior to the onset of the headache. 
All five subjects were scanned within 24 hours of onset of migraine. The mean time 
from onset to scan was 11 hours. Comparing the scans collected during migraine with 
those out of the attack revealed significant activations in the rostral, dorsal pons, 
lateralised to the left (Figure 7.1). After small volume correction the activation was 
significant at the cluster level (P = 0.003, corrected).
Responses were also seen in the right anterior cingulate, posterior cingulate, 
cerebellum, thalamus, insula, prefrontal cortex and temporal lobes (Table 7.2a, 
Figure7.3). Interestingly, there was an area of deactivation in the migraine phase also 
located in the pons, lateralised to the right (Table 7.3, Figure7.2). This was an 
unexpected finding and reached the recommended level of significance for 
exploratory analysis {P < 0.05, corrected).
Analysis o f flipped data
After flipping the images so that, effectively, all the migraines were on the right side, 
the area of activation in the left, dorsal pons remained. A small area in the right 
anterior pons was also noted which was not seen in the first (unflipped) analysis.
Comparison of the flipped and unflipped data to assess for areas that lateralise with 
side of pain revealed activation of the thalamus (see Table 7.2b). This was the only 
area of activation to lateralise with side of pain.
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Table 7.1 Subject characteristics
Patient Diagnosis Age Nausea Photophobia Phonophobia Worse with 
movement
Laterality of headache Attack freq 
/month
Aura
1 MO 45 + + + + Right 4
2 MO 30 + + Left 4
3 MWA 48 + + + + Left 1 Visual
distortion,
clumsy
4 MWA 55 + + + + Right 4 Paraesthesia,
incoordination
5 MO 54 + + Right 1
MO-Migraine without aura, MWA-Migraine with aura
Table 7.2 Areas of activation in migraine state compared to inter-ictal state, 
a) Primary analysis, b) Flipped analysis.
The coordinates refer to voxels significant at P < 0.001 (uncorrected).
* also significant at the cluster level (cluster size = 90 voxels), P  = 0.003 (corrected 
for multiple comparisons across a 12mm radius sphere centred on the brainstem 
maxima as reported, 
a) Primary analysis
Region of activation Coordinates x,y,z Z score of peak
(Talairach andTournoux) activation
Anterior cingulate BA24/32(R) 4,30,19 4.66
Posterior cingulate BA23 0,-45,34 Infinite
0,-20,38 7.84
Prefrontal cortex BA9/10 (R) 6,57,16 6.01
Cerebellum- (R) 12,-67,-15 4.95
(L) -10,-42,-12 5.19
Thalamus (R ) 10,-6,8 4.82
Insula (L) -40,14,3 4.10
Dorsal pons (L) -4,-28,-20 4.97*
Temporal lobe (L) -42,12,-24 5.21
(R) 34,18,-18 6.19
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b) Flipped analysis
Region of activation Coordinates x,y,z Z score of peak
(Talairach and Tournoux) activation
Anterior cingulate BA24/32 (R) 2,28,20 3.81/3.95
16,12,28
Posterior cingulate BA23 0,-20,38 7.84
(R) 2, -44, 34 Infinite
Prefrontal cortex BA9/10 (R) 6,49,14 5.29
Cerebellum- (R) 10,-64,-14 4.29
(L) -10,-44,-14 5.09
Thalamus (L) -8,-4,14 3.96
Insula (R) 44,12,0 3.85
(L) -36,-14,1 3.92
Dorsal pons (L) -2,-28,-22 4.6
Anterior pons (R) 8,-12,-22 3.53
Temporal lobe (L) -40,12,-24 5.45
(R) 36,14,-14 5.83
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Table 7.3 Area of deactivation in migraine state compared with inter-ictal state. The 
coordinates refer to the peak voxels within a cluster P < 0.05 (corrected for multiple 
comparisons across whole brain volume). **Cluster size = 74 voxels.
Region of activation T+T coordinates Z score
Pons(R ) 14,-28,-20 5.4**
Region of activation after 
flipping
T+T coordinates Z score
Pons(R) 16,-28,-19 5.4
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Fig 7.1 Activation in the dorsal pons in the migraine state compared to inter-ictal 
state.
Fig 7.2 Area of deactivation in migraine state compared to inter-ictal state.
Fig 7.3 Activation in the thalamus and insula in migraine state.
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Discussion
These new data supplement and support previous findings of activation of the 
dorsolateral pons in migraine. In addition there is activation of other structures 
involved in various aspects of pain and related processing in the brain. In addition we 
have observed deactivation in the contralateral pons, a new finding in migraine. Our 
results are consistent with a view of migraine as primarily a subcortical disorder 
involving dysfunction in brainstem areas probably involved in the modulation of 
sensory processing.
The areas of activation in the brain reported here include regions thought to be 
involved in the central pain matrix (Derbyshire, 2000). The anterior cingulate has 
been the most consistently activated area in pain studies. It is thought to be involved 
in the affective and evaluative dimension of pain. In particular, the right anterior 
cingulate was found to be active irrespective of the afflicted side in a study of patients 
with acute cluster headache (Hsieh et al., 1996). The posterior cingulate is relatively 
less frequently activated in response to pain (Kwan et al., 2000). The insula is also 
consistently activated in experimental pain studies. It has connections with the limbic 
system and the autonomic system and is thought to be involved in representing the 
emotional aspect of pain. The thalamus, which is the relay centre for afferent input to 
the brain and the cerebellum, is less consistently activated in experimental pain 
studies. The prefrontal cortex is involved in the cognitive emotional processing of 
pain (Ingvar, 1999). Activations in the temporal lobes were also found in the Weiller 
study and these were in the auditory association areas.
The area of deactivation was an unexpected finding, not previously reported. It is of 
interest to note that it was on the opposite side of the pons to the area activated during
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the migraine state. It is possible that as one area of the pons is activated another 
region is deactivated. In this regard it is known that the locus coeruleus which is in the 
dorsolateral pons and contains neurons that account for 96% of brain noradrenergic 
projections (Amaral and Sinnamon, 1977), has such a reciprocal contralateral 
inhibitory effect (Buda et al., 1975).
The main area of the brain which was dependent on the anatomical location of pain 
was the thalamus. There is evidence that pain processing is lateralized in humans.
This is discussed, to some extent, in section 2.3. Hsieh and colleagues (1995; 1996) 
demonstrated that the right anterior cingulate is activated irrespective of side of pain. 
PET studies have mainly found bilateral activation of the thalamus (Casey et al.,
1996). However, more recently Bingel and colleagues (Bingel et al., 2003) 
demonstrated that the lateral thalamus, but not the medial thalamus, showed a 
contralaterally biased representation of painful stimuli. The lateral thalamus is thought 
to be somatotopically organized and therefore is involved in localization and 
discrimination of stimuli (Ingvar, 1999). This is consistent with our finding of 
contralateral activation of the thalamus after the scans were flipped.
Unfortunately the number of patients completing the study was not as many as we had 
initially planned, although this does not detract from our positive results there may be 
other areas that we have not detected. Unlike previous imaging studies in migraine 
our study included subjects with both migraine with and without aura although the 
latter group were scanned after the aura had subsided.
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Conclusion
Our data demonstrate activation of the dorsolateral pons on the left side during acute 
migraine with associated deactivation of the contralateral pons. Areas of activation, 
such as the anterior cingulate, prefrontal and insula cortex, were seen and are 
consistent with areas seen during studies involving acute pain. The thalamic activation 
was found to be lateralized contralateral to the side of pain, which is consistent with 
known anatomy.
97
Chapter 8. A PET study exploring the laterality of brainstem 
activation in migraine using GTN
Introduction
The headache in migraine may be unilateral or bilateral. The largest positron emission 
tomography (PET) study in migraine to date involved nine migraineurs with right­
sided headache (Weiller et al., 1995). The finding of brainstem activation lateralised 
to the left raised the question of whether activation is always contralateral to the side 
of headache. Exploring this issue would provide an important insight into the 
functional anatomy of primary headache, in particular migraine.
Because of the episodic nature of migraine it is challenging to perform clinical 
studies, in particular functional imaging studies. The glyceryl trinitrate (GTN) model 
of migraine has become established as a relatively reliable and effective method of 
migraine induction (as detailed in previous chapters).
In this study we use the intravenous GTN model to enable the study of a migraine 
attack from its earliest point and to follow it through to its resolution after therapeutic 
intervention. To our knowledge there have been no H2150  PET studies of GTN 
induced migraine with the exception of a single case report (Bahra et al., 2001). PET 
has been used to study healthy controls following administration of intravenous GTN 
and this revealed regional activation in areas of the large intracranial vessels and the 
anterior cingulate cortex (Bednarczyk et al., 2002). We were particularly interested in 
a comparison between the PET findings in induced migraine and earlier PET findings 
of brainstem involvement in spontaneous migraine (Weiller et al., 1995). Further we
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sought to extend previous work to examine the laterality of brain changes in migraine 
since this is such a key feature of the characteristic clinical picture.
Methods
Patients
Twenty-four migraineurs (aged 26-65, 10 male, 14 female) were divided into three 
groups according to the location of their usual migraine headache: eight right-sided, 
eight left-sided and eight with bilateral headache (Table 8.1). All of these fulfilled 
International Headache Society criteria for episodic migraine (Headache 
Classification Committee of The International Headache Society, 2004) and included 
eight with migraine with aura and sixteen with migraine without aura. The 
migraineurs were not on any prophylactic medications. Other medications included 
the oral contraceptive pill in four of the subjects, HRT in three subjects and thyroxine 
in two of the subjects. All were successfully scanned during an induced migraine. 
Eight healthy controls were also studied (aged 21-55, 5 male, 3 female). The controls 
were recruited on the basis of no personal or family history of migrainous headaches 
and no history of frequent tension-type headaches. They were excluded if they were 
on any regular medication. Pregnant women were excluded from the study and a 
pregnancy test was performed in women of child-bearing age.
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Glyceryl trinitrate infusions
Each subject received an intravenous infusion of 0.5 pg/kg/min glyceryl trinitrate 
(GTN) over twenty minutes via a cannula inserted into the right antecubital vein. This 
dose has been validated in previous studies (Iversen, 2001). The migraineurs were all 
headache free for at least 48 hours prior to the initiation of the infusion. No triptans or 
analgesics had been taken in the preceding 48 hours. Headache intensity and 
characteristics were recorded every 5 minutes during the infusion and every 15 
minutes for up to four hours after the infusion. Subjects were periodically asked to 
describe any headache or other associated symptoms such as nausea, photophobia, 
phonophobia, or worsening of pain on head movement. In addition, they rated the 
severity of any headache on a verbal rating scale of 0-10 (0 = no pain, 10 = most 
severe pain imaginable) and the location and nature of any headache was noted. Blood 
pressure and pulse were monitored during infusions.
Subjects were also questioned about premonitory symptoms, such as yawning, 
fatigue, neck stiffness, thirst, frequency of urination, cravings or mood change (Giffm 
et al., 2003). In the migraine subjects whose migraines were successfully triggered 
subcutaneous sumatriptan (6mg) was administered to abort the attack and the time 
taken for relief was noted. These subjects were invited back for a repeat session, at 
least a week later, in order for them to undergo PET scanning.
PET scanning
The subjects (migraineurs and controls) underwent 3 consecutive PET scans in each 
of the following four conditions (Figure 8.1):
1) Pain free
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2) During the non-specific headache of a GTN infusion
3) During a migraine headache, or equivalent time delay for controls
4) Pain free following treatment of migraine with subcutaneous sumatriptan 6mg. 
The time between conditions two and three (the latency of onset of migraine) varied 
and this delay was reproduced for the control scans as the controls did not have 
headache during condition three. This enabled the controls’ scans to be yoked to the 
migraineurs’ scans. During each scan the subjects were again asked to rate their 
headache using a scale of 0-10 (0 = no pain, 10 = most severe pain imaginable) and to 
describe the nature and location of the headache along with non-headache features 
including premonitory symptoms. All subjects were asked to close their eyes during 
scanning.
Data acquisition and analysis
PET scans were performed with an EC AT EXACT HR+ scanning system (CTI 
Siemens, Knoxville, TN) in three-dimensional mode with septa retracted. SPM99 
(Wellcome Department of Imaging Neuroscience, http://www.fil.ion.ucl.ac.uk/spm) 
was used for data analysis (Frackowiak and Friston, 1994). Images were realigned 
with the first as the reference and then co-registered, and finally spatially normalised 
into the space defined by the atlas of Talairach and Toumoux (Talairach and 
Toumoux, 1988). The normalised images were smoothed with a Gaussian filter of 10 
mm full width at half-maximum. Statistical parametric maps were derived with pre­
specified contrasts, comparing regional cerebral blood flow during headache versus 
rest. An uncorrected threshold of P < 0.001 was chosen for tabular and graphical 
reporting. In areas with a prior anatomical hypothesis, the reporting criterion was P < 
0.05 applying a small volume correction for multiple non independent comparisons
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using a 12 mm radius sphere centred on the brainstem maxima as reported 
(coordinates:-2, -28, -22) (Bahra et al., 2001). The first analysis was performed using 
a model that enabled group by condition interactions. This allowed us to discount 
order and other non-specific effects shared with the controls. The PET scans from the 
left-sided group were reflected through the sagittal plane (flipped) to analyse all the 
migraine subjects as one group (incorporating right-sided, flipped left-sided and 
bilateral migraineurs) in a comparison with the control group. This technique enabled 
us to look for the main effect of migraine in terms of contralateral and ipsilateral 
effects over all subjects (as opposed to left and right effects). Having established the 
group by condition interactions were significant we proceeded to examine the simple 
main effects of condition. To examine laterality of rCBF changes with respect to side 
of pain, a migraine versus pain-free contrast (condition 3 versus condition 1) was then 
performed for each group of patients separately. Finally, to test for bilateral changes a 
conjunction analysis was performed. This was done by comparing the migraine versus 
pain-free contrast in a statistical model that included both flipped and unflipped scans 
for each of the migraine groups. The conjunction analysis tests for the presence of 
significant changes in rCBF in the flipped and unflipped scans simultaneously, 
therefore a bilateral effect will appear as a significant conjunction (Friston, 2003). The 
model also included time (scan number) as a nuisance variable, which was modelled 
separately for each group.
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Results
Clinical findings
All of the migraineurs and six of the controls experienced a very mild, non-specific 
headache during the GTN infusion. In the migraine group the mean VAS pain severity 
rating for this headache was 2.5 out of 10 and in the control group it was 1 out of 10. 
In the migraine group this eventually developed into a typical migraine headache, 
fulfilling IHS criteria for migraine (Headache Classification Committee of The 
International Headache Society, 2004), whereas in the control group the headache 
subsided within a few minutes of the end of the GTN infusion. The mean VAS pain 
severity rating in the migraine group at the time of acquisition of “migraine scans” 
was 5 out of 10.
The migraine group included migraineurs with and without aura. The GTN method of 
inducing migraine has been shown to induce migraine without aura in subjects who 
have migraine with aura (Christiansen et al., 1999). This was the case in seven of our 
eight subjects with migraine with aura. However in one of them a typical visual aura 
was induced along with the headache.
It is also of interest that a significant number (50%) of the migraineurs described 
typical premonitory symptoms, such as yawning, tiredness, irritability, neck stiffness, 
frequency of urination, hunger and low mood following the GTN trigger (see Chapter
PETfindings
Given the previous PET findings in migraine (Weiller et al., 1995) the main focus of 
our analysis was on the brainstem although other areas of activation were also 
observed and are reported.
Main effect o f  migraine over all groups
The main effect of migraine was obtained by comparing condition 3 versus 1 in all 24 
migraine subjects with condition 3 versus 1 in the control subjects (Figure 8.1). 
Significant brainstem activation was seen in the dorsal pons and rostral medulla (P < 
0.05 after small volume correction) (Table 8.2, Figure 8.2). Following abortion of the 
migraine with sumatriptan the dorsal pons remained activated.
Other areas of activation present in the migraine state included the anterior cingulate, 
bilateral insula, bilateral cerebellar hemispheres, prefrontal cortex and the putamen 
(Table 8.2).
Main effect o f  GTN
This was obtained by comparing condition 2 versus 1 in all 24 migraine subjects with 
condition 2 versus 1 in the control subjects.
During the GTN infusion the migraineurs experienced a mild, non-migrainous 
headache which faded as soon as the infusion was complete. No activation in the 
dorsal pons was detected. However, activation was seen in the anterior cingulate and 
in regions corresponding to the internal carotid and basilar arteries (Figure 8.3).
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Migraine with aura versus migraine without aura
The 24 migraineurs included 8 with a diagnosis of migraine with aura and 16 with 
migraine without aura. Analysis of the data revealed activation in the dorsal pons in 
both sub-groups.
Laterality o f  brain changes in each group
The brainstem was the main focus for examining lateralised changes in activation 
with respect to side of pain (refer to Table 8.3 for coordinates of activation).
In acute right-sided migraine activation was seen in the right dorsal pons and in the 
rostral medulla near the mid-line (Figure 8.4).
In acute left-sided migraine a small area of activation was seen in left dorsal pons 
(Figure 8.4).
In acute migraine with bilateral pain activation was seen in the left dorsal pons. A 
formal conjunction analysis with flipped scans (see Methods) revealed a bilateral 
component to the dorsal pontine activation in this group.
Other areas o f  significant activation examined for lateralisation 
Right anterior cingulate activation, bilateral insular and bilateral cerebellar activations 
were consistently seen in the migraine groups during headache (uncorrected P < 
0.001). Bilateral prefrontal activation was found in all groups except in the right-sided 
group where it was left-sided only. Occipital lobe activation was seen in the left-sided 
group. Temporal lobe activation was found in the right and left groups.
Basal ganglia activation (putamen, caudate nucleus) was found in the right sided and 
bilateral group.
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Figure 8.1 Study Design
Condition 1 Condition 2 Condition 3 Condition 4
Pain free GTN headache Migraine Pain free
GTN infusion Sumatriptan
106
Figure 8.2
Activation of the dorsolateral pons in migraine patients during a glyceryl trinitrate 
(GTN) triggered attack when compared to matched controls administered GTN in the 
same time course (4,-32,-32).
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Figure 8.3
Activation in migraine patients during GTN infusion and non-specific headache 
compared to matched controls. Regions of activation demonstrated involve the 
internal carotid artery and its branches.
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Figure 8.4
Activation of the ipsilateral pons in patients with right sided attacks (n = 8, a) and left 
sided attacks (n = 8, b).
a
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Table 8.1 Subject characteristics 
Right-sided migraine group
Patient Diagnosis Age Nausea Photophobia Phonophobia Worse with 
movement
Aura Attack freq 
/month
1 MWA 29 + - + + Paraesthesia R arm 1
2 MO 45 + + + + 1
3 MO 29 + - + + 3
4 MO 48 + + + + 4
5 MO 27 + + - + 2
6 MO 26 - + + + 2
7 MO 60 - + + + 8
8 MWA 28 + + + + Visual patterns 1
Left-sided migraine group.
Patient Diagnosis Age Nausea Photophobia Phonophobia Worse with 
movement
Aura Attack freq 
/month
1 MO 47 - + + + 1
2 MO 47 + + + + 2
3 MO 28 + +
- - 4
4 MWA 54 + + - - Visual, speech 
disturbance
3
5 MO 65 - + + - 2
6 MO 53 + + + - 4
7 MWA 58 + + + + Visual patterns 4
8 MWA 54 + + + - Visual zig-zag pattern 8
Bilateral migraine group
Patient Diagnosis Age Nausea Photophobia Phonophobia Worse with 
movement
Aura Attack freq 
/month
1 MO 55 - + + + 4
2 MWA 54 + + + + Visual scotoma, 
paraesthesia
1
3 MWA 65 + + + + Visual -lights 8
4 MO 51 - + + + 1
5 MO 41 + + + + 6
6 MO 56 + + + + 2
7 MO 59 + + + - 3
8 MWA 58 + + + + Visual lines 8
Table 8.2 Main effect of migraine.
Migraine group pooling right sided, bilateral and flipped left-sided migraineurs. The 
Talairach and Toumoux coordinates describe the maxima within a cluster defined as 
the voxel with the highest Z-score (P < 0.001, uncorrected).
*A small volume correction (SVC) was applied to the brainstem area (as described in 
methods section).
BA-Brodmann area
Area of activation Coordinates x,y,z Z score of 
peak
activation
Dorsal pons* 4, -32, -32 3.95 
(P=0.01 SVC)
Anterior cingulate BA24 10,30,-4 3.95
Prefrontal cortex BA 10 -18,46, -2 4.43
Insula- right 32, 20,10 4.62
left -60, 4, 8 4.3
Cerebellum-right 40, -82, -30 3.62
left -24, -66,-14 4.8
Putamen -20,0,12 4.95
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Table 8.3 Site of brainstem activation in each migraine sub-group. The Talairach and 
Toumoux coordinates describe the maxima within a cluster (P < 0.001). A small 
volume correction (SVC) was applied (as described in methods section) using a 
reporting criterion of .P<0.05 corrected for multiple comparisons.
Group Area of activation Coordinates x,y,z Z score of 
peak activation
P value 
(SVC)
Right-sided Dorsal pons (right) 8,-32,-28 4 0.02
headache Rostral medulla (mid­
line)
0,-32,-40 4.25
Left-sided
headache
Dorsal pons (left) -4,-34,-28 3.4 0.03
Bilateral headache Dorsal pons (left) -4,-32,-20 3.9 0.01
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Discussion
This study demonstrated robust activation of the dorsolateral pons in clinically typical 
migraine triggered by glyceryl trinitrate (GTN). By selecting patients with habitually 
lateralised attacks, and testing this lateralisation in a pre-scanning session, we showed 
that patients with right-sided pain activate the right dorsolateral pons and patients with 
left-sided pain activate the left dorsolateral pons. By comparison, patients with 
bilateral pain activate the left side of the dorsolateral pons predominantly but a 
conjunction analysis reveals that in fact there are bilateral activations present. 
Brainstem activation has been reported previously in spontaneous migraine and 
triggered migraine (Bahra et al., 2001; Weiller et al., 1995). In both the Weiller study 
(Weiller et al., 1995) and our current study activation persists after pain control is 
achieved with sumatriptan. The data suggest that unilateral pain, one of the hallmark 
features of migraine, results from an asymmetrical brain dysfunction. We infer that 
the persistence of activation after pain control reflects an underlying abnormality in 
the disorder and not simply a response to pain.
Study limitations
Other than the different design, PET camera and analysis an important difference 
between this study and that of Weiller and colleagues (Weiller et al., 1995) is the use 
of GTN triggering. Studying triggered attacks allows considerably more experimental 
control and permitted us to carefully select patients with habitually right, left or 
bilateral pain, and to pre-test their responses. In addition, we used a non-headache 
group to control for order or time effects. There are several reasons to conclude that 
GTN-triggered attacks are migraine. First, their clinical phenotype is indistinguishable
115
from spontaneous migraine (Headache Classification Committee of The International 
Headache Society, 2004; Iversen et al., 1989). Secondly, their response to treatment 
with triptans is the same (Ferrari et al., 2001; Iversen and Olesen, 1996). Thirdly, 
triggering of migraine is itself a fundamental feature of the disorder, so that a so 
called “spontaneous attack”, triggered for example by missed sleep, is not 
differentiated in clinical practice. Fourthly, the GTN model reproduces premonitory 
symptoms (Afridi et al., 2004), again a typical feature of spontaneous attacks (Giffin 
et al., 2003) as well as the laterality of the patients usual migraine attack. Also, 
nitrergic mechanisms seem fundamental in migraine (Olesen et al., 1994) with 
blockade of its synthesis aborting acute migraine (Lassen et al., 1997). However, we 
cannot exclude some difference that cannot be accounted for by our study design. Our 
migraine subjects were pre-selected on the basis of response to GTN as a trigger of 
migraine. It is possible that this may introduce some selection bias. However, studies 
of the GTN model suggest that 75-80% (Afridi et al., 2004; Sances et al., 2004; 
Thomsen et al., 1994) of migraineurs may be responsive to GTN triggering, 
suggesting that this sub-group represents a reasonably large proportion of the overall 
migraine population.
Another issue that needs consideration is the timing of attacks. Since we induced 
migraine we could study attacks early, acquiring imaging data as soon as patients had 
reasonably developed headache with a mean pain severity rating of 5 out of 10. It is 
possible that the activation switches sides during an attack if pain develops further, 
although one could speculate that this was a response to the initial homolateral 
dysfunction. This is one possible explanation for the difference between our findings 
and those of the Weiller study (Weiller et al., 1995) in which patients were scanned 
later. Certainly, the data from our patients with bilateral pain suggest that localisation
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of pain is very closely linked to the side of brainstem activation. Lastly, by including a 
control group matched for time and GTN administration it seems unlikely that the 
effect we report is a non-specific effect of GTN or an order effect. The latter is crucial 
since brain activation in other pain states, such as hypothalamic activation with 
cardiac pain (Rosen et al., 1994), has been subsequently shown to be due to an order 
effect when an appropriate control group was included (Rosen et al., 1996).
Conclusion
This study provides an insight into the neuroanatomical changes associated with 
migraine. The data reinforce a view of migraine as a brain disturbance and suggest 
that lateralised change in the brain, particularly in the dorsolateral pontine tegmentum 
may answer the age old question of why the head hurts on just one side.
117
Chapter 9. Occipital activation in GTN-induced migraine with aura
A small but significant proportion of migraineurs (30-40%) have migraine with aura 
most commonly in the form of visual disturbances such as scintillating scotoma 
(Launer et al., 1999; Stewart et al., 1994). Leao (Leao, 1944) first described the 
phenomenon of spreading depression when he found that noxious stimulation of 
rabbit cerebral cortex produced a spreading decrease in electrical activity moving at a 
rate of 2-3 mm/min. This rate corresponds well with the propagation of visual aura 
(Hadjikhani et al., 2001). It has been proposed that this cortical spreading depression 
represents the neurobiological basis for migraine aura whereby neuronal activation 
and suppression are followed by corresponding vascular changes (Lauritzen, 1994).
It has been difficult to image patients with migraine aura because functional brain 
imaging is technically demanding and spontaneous attacks are unpredictable. While 
nitric oxide (NO) donors have long been recognised to trigger severe headache (Laws, 
1898), and indeed to trigger migraine (Iversen, 2001), it has generally not been 
recognised to trigger migraine aura even in those who have had it spontaneously 
(Christiansen et al., 1999).
Case
A 54 year old male with episodic migraine with aura volunteered to participate in a 
positron emission tomography (PET) study in migraine. He had a history of migraine 
with aura as defined by the International Headache Society Criteria (Headache 
Classification Committee of The International Headache Society, 2004) since his 
teenage years with a frequency of up to eight attacks per month each lasting up to one
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day if left untreated. A typical attack would begin with visual aura in the form of 
bright, flashing zig-zag shapes moving around his visual field and rarely he 
experienced macropsia. The visual aura would last 10-20 minutes and would be 
followed by a left-sided headache with associated nausea, photophobia, phonophobia 
and aggravation by movement. His attacks were usually aborted within 2 hours using 
zolmitriptan. He had no other significant medical conditions. His father also suffered 
with migraine with aura.
Glyceryl trinitrate triggering: An intra-venous infusion of 0.5 pg/kg/min glyceryl 
trinitrate (GTN) was administered over 20 minutes on two occasions separated by one 
week with the aim of inducing a migraine. On both occasions a migraine was 
successfully triggered, after 150 minutes and 165 minutes, respectively. The subject 
underwent PET scanning during the second session of GTN.
A visual aura typical of the subject’s previous attacks was also triggered during both 
sessions of GTN. He described flashing bright zig-zag patterns spreading across his 
visual field lasting 10 minutes. He was unable to describe any laterality of the visual 
symptoms. The aura remained unchanged by eye closure. This was then followed by 
a left-sided migrainous headache. Subcutaneous sumatriptan (6mg) was then 
administered to the subject and the migraine attack was successfully aborted.
PET scanning and analysis: The subject was scanned prior to the infusion, while pain 
free, and during the aura and headache phases of migraine. He described the onset of 
the aura and scanning of the aura phase commenced immediately following this 
description. PET scans were performed with an ECAT EXACT HR+ scanning system
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(CTI Siemens, Knoxville, TN) in three-dimensional mode with septa retracted as 
described in chapter 8. He had his eyes closed throughout the scanning sessions.
The subject had a total of twelve scans, two of which were during the aura. The aura 
subsided during the second of the scans. The interval between scans was 8 minutes. 
SPM99 was used for data analysis (Frackowiak and Friston, 1994). Statistical 
parametric maps were derived with pre-specified contrasts, comparing regional 
cerebral blood flow during aura versus rest. An uncorrected threshold of P < 0.001 
was chosen for tabular and graphical reporting.
Results
Analysis of the PET data revealed right-sided occipital activation when comparing the 
two scans taken during the visual aura with those taken immediately prior to the GTN 
infusion (Figure 9.1). The activation was in the primary visual region (VI) of the 
occipital cortex (Brodmann area 17). This area has a very high degree of retinotopic 
precision and orientation selectivity (Tootell et al., 1998). No significant activation 
was observed in the VI region of 7 other patients with IHS defined migraine with aura 
who developed migraine without aura following GTN administration (Afridi et al., 
2004).
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Figure 9 Right-sided occipital activation during visual aura.
The Talairach and Toumoux (1988) coordinates of peak activation within the cluster 
are (14, -82, 8). The Z score at peak activation is 4.4 (uncorrected P  < 0.001).
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Discussion
As far as we are aware there have not been any published reports of PET activation in 
the primary visual cortex during visual aura. Earlier studies using PET and SPECT 
demonstrated spreading hypoperfusion in the occipital cortex in migraine with aura 
(Olesen et al., 1981; Woods et al., 1994). More recently functional MRI has been used 
in migraineurs to investigate occipital cortex activation during visual stimulation with 
a checker board. In one of these studies an initial increase in blood flow was 
demonstrated in the extrastriate cortex (V3A) (Hadjikhani et al., 2001). This signal 
progressed across the occipital cortex (including VI) and was followed by diminution 
of the signal. The authors proposed that these changes represented cortical spreading 
depression. In a previous fMRI study (Cao et al., 1999) the process was described in 
another subject with visually triggered visual aura. In this case it was initiated in the 
primary visual cortex and then spread anterolaterally. Unfortunately the relatively 
poor temporal resolution of PET did not allow us to follow the progression of the aura 
more closely in our case.
Our patient was a participant in a study involving GTN triggering of migraine and 
was one of two patients in whom migraine aura was triggered (Afridi et al., 2004). 
Unfortunately the second patient did not undergo PET scanning. The mechanism by 
which GTN triggers migraine is unclear but it is thought that the exogenous NO from 
the GTN may induce endogenous NO production. Animal studies have also revealed 
that cortical spreading depression, which is thought to be responsible for migraine 
aura in humans, elicits widespread release of NO and increased cortical 
concentrations of cyclic guanosine monophosphate (Read et al., 2001). The CSD
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induced increase in cortical NO is reduced when sumatriptan is given as a pre­
treatment in cats and rats (Read and Parsons, 2000).
Other possible causes for the occipital activation in this patient include the possibility 
that he opened his eyes during the scanning, although the patient denies this and if this 
was the case then one would expect a much greater pattern of activation in the visual 
cortex than that observed. Another possibility is that the GTN is responsible for 
vasodilatation in the occipital cortex. However, the region of activation is localised 
and unilateral and one would expect a GTN related flow change to be bilateral and 
generalised. In fact bilateral hypoperfusion rather than hyperperfusion has been 
documented in the occipital cortex following GTN administration to healthy controls 
(Bednarczyk et al., 2002). It is possible that some inherent neurovascular asymmetry 
exists in the brains of migraineurs which may alter the vascular response to GTN. 
However, this does not explain the lack of significant activation in the V 1 region in 
any of the other patients with migraine with aura who received GTN infusions. It is 
also of interest to note that activation in VI has been documented during visual 
mental imagery in particular when the subjects are required to imagine high resolution 
detailed images (Kosslyn et al., 2001).
Ours is the first case to show that aura can be triggered reproducibly by GTN making 
it less likely that the aura was spontaneous or developed by chance in this situation. 
The fact that the site of activation was contralateral to the headache does not 
contradict our explanation for the findings since we are proposing that the V 1 
activation is related to the aura and not the headache. Clinical and experimental 
observations (Olesen et al., 1990; Selby and Lance, 1960) have shown that aura
123
symptoms are not always contralateral to headache and consequently aura associated 
changes in brain activation may be contralateral to headache. While some take the 
view that aura is triggers headache (Moskowitz et al., 2004), others have argued for a 
dissociation (Goadsby, 2001).
Conclusion
We present evidence for the reproducibility of GTN as a trigger of migraine aura and 
using PET we have demonstrated activation in the primary visual area of the occipital 
cortex during the aura. While the number of patients who can have aura reliably re­
triggered is small, such cases clearly exist and may offer insights into the 
neuroanatomical correlates of this fascinating clinical symptom.
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PART IV. DISCUSSION
How do the brainstem findings relate to the clinical picture? 
Dural Vessels Pial Vessels
To Thalamus
O
PAG
DR
TG
LC
NRM
TNG
Figure 10.1 Brainstem structures and pathways involved in migraine 
TG-trigeminal ganglion, TNC- trigeminal nucleus caudalis, PAG- periaqueductal 
gray, DR-dorsal raphe, LC-locus coeruleus, NRM- nucleus raphe magnus, IV-fourth 
ventricle.
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The two PET studies provide further evidence for the involvement of the brainstem in 
migraine. Weiller et al. initially proposed the brainstem as “a generator” of migraine. 
It cannot be concluded from these studies whether the brainstem generates or 
modulates migraine. Our findings suggest that it is possible to relate the anatomical 
involvement to the clinical picture. First, the brainstem is an integral part of the 
descending, and probably ascending nociceptive inhibition system and one of the 
cardinal features of migraine is pain. However, the migraine state does not reflect 
head pain in isolation. Indeed, there are a number of associated features which require 
consideration in a discussion regarding the pathophysiology of migraine.
Phonophobia and photophobia have been described inter-ictally as well as ictally 
(Main et al., 1997; Woodhouse and Drummond, 1993). Taking phonophobia, it has 
been proposed that a transient, peripheral defect such as cochlear dysfunction 
secondary to disturbances in the vertebro-basilar system may be responsible (Kayan 
and Hood, 1984). However cochlear dysfunction should lead to loudness recruitment 
which would result in a decrease in auditory sensitivity during migraine and this was 
not shown to be the case in a study of migraineurs (Woodhouse and Drummond,
1993). The presence of inter-ictal and often bilateral symptoms also goes against a 
transient peripheral dysfunction. These are more likely to be the result of a 
dysfunction of central sensory processing. Brainstem auditory evoked potentials have 
been shown to be modulated by the serotonergic system (Bank, 1991; Sand and 
Vingen, 2000) and there is a well described lack of habituation of BAEP in 
migraineurs inter-ictally (Schoenen, 1998). The brainstem noradrenergic system is 
known to affect signal-to-noise ratio of sensory processing and this will be discussed 
later. New onset phonophobia has also been reported as a result of a demyelinating 
pontine lesion (Weber et al., 2002). It is of interest to note that in this case the
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phonophobia was ipsilateral to the pontine lesion. Similarly, taking photophobia as an 
example, the anatomical dysfunction responsible for this symptom could, in theory, 
occur at any point from the retina to the occipital cortex. Using Occam’s razor one 
would postulate that the abnormality which results in the various combinations of 
symptoms in migraine lies in one specific region of the brain. The interaction between 
pain, photophobia, phonophobia and nausea favours a central dysfunction rather than 
multiple peripheral defects. Drummond et al. have performed numerous studies 
looking at the interplay of these symptoms and demonstrated that painful stimulation 
of the trigeminal system increases photophobia and nausea in migraineurs and also 
that nausea intensifies facial pain (Drummond and Granston, 2004; Drummond and 
Woodhouse, 1993). The interplay is suggestive of a central dysmodulation in a region 
of the brain which could account for such symptoms. The obvious choice would be 
the brainstem where it is known that modulation of sensory information occurs and 
pathways exist between the TNC and the medullary nuclei of the solitary tract 
(Ruggiero et al., 2000). It is interesting to note that painful stimulation from another 
region of the body (the hand) did not produce the same effect as painful stimulation of 
the temple suggesting that it is not simply a non-specific response to pain.
If the migraine process was initiated and driven peripherally from the trigeminal 
fibres then one would not expect there to be any abnormalities inter-ictally. However 
there is evidence that abnormalities exist during the inter-ictal period both from 
electrophysiological studies (described earlier) and from clinical studies showing that 
migraineurs may be more light-sensitive (Drummond, 1997; Drummond and 
Woodhouse, 1993; Vanagaite et al., 1997), noise-sensitive (Main et al., 1997) and in 
some cases more pain-sensitive (Marlowe, 1992; Nicolodi et al., 1994; Weissman-
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Fogel et al., 2003). This suggests an underlying defect in sensory regulation which 
becomes exacerbated during the migraine. The brainstem is an ideal candidate for 
such a region and the work presented in this thesis supports such a notion.
Arguments against the significance of the brainstem findings
One argument that has been proposed is that the activation seen in the PET studies in 
migraine is simply a response to pain. Indeed, activation of the PAG has been 
described in 37-40% of functional imaging studies of experimental pain (Derbyshire, 
2000). However, this activation is restricted to the midbrain and pontine activation has 
not been described in PET studies of pain although it was found in a recent fMRI 
study looking at empathy for pain amongst partners (Singer et al., 2004). It may be 
that with the advent of more sensitive functional imaging techniques pontine 
activation may be detected increasingly in pain studies, however this remains to be 
seen. In another fMRI study examining the placebo effect there was no pontine 
activation during the “pain only”condition but activation was present when opiod and 
placebo were administered following pain (Petrovic et al., 2002). A problem arises 
when one compares imaging findings in migraine studies to those in general pain 
studies which is the fact that these studies may include migraineurs as “healthy 
controls”. Given the difficulty in finding pure non-migraine controls and the 
prevalence of migraine in the general population it is likely that subjects with 
migrainous biology would inadvertently have been included in general pain imaging 
studies as “healthy controls”.
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Another possible suggestion is that the brainstem activation observed is in the 
trigeminal nuclei. This is highly unlikely as the activation would tend to involve the 
TNC which is more caudal. In fact, an area of activation in the rostral medulla was 
noted in addition to the pontine activation in the right-sided induced migraine group 
(chapter 8). Trigeminal nucleus activation in response to noxious heat stimuli has 
been mapped using fMRI and the activation is, as expected, in the medulla rather than 
the pons (DaSilva et al., 2002) (see Fig 10.2). Also previous PET and MRI studies of 
experimental facial pain (May et al., 1998b), cluster headache (May et al., 1998a) and 
SUNCT (May et al., 1999) do not demonstrate brainstem activation. However, the 
recent finding of brainstem activation in hemicrania continua (Matharu et al., 2004b) 
is noteworthy since the phenotype of this condition shares many common features 
with migraine and is often clinically difficult to distinguish. Interestingly, in the 
aforementioned study the activation was also ipsilateral to the side of pain.
One of the arguments against a primary central (brainstem) mediated sensitisation or 
modulation of gating being responsible for the pain in migraine is that pain and 
allodynia are often localised and critics of the brainstem theory argue that a general 
dysfunction of brainstem nociceptive structures would imply a generalised pain state. 
However, there is evidence for somatotopic organisation of the PAG (Soper and 
Melzack, 1982) and it has also been shown that there is a differential pattern of 
response of cells in the RVM depending on the anatomical area stimulated (Ellrich et 
al., 2001b; Watkins et al., 1980). There is evidence of functional anatomical 
organisation within the dorsal raphe projection system from animal studies (Kirifides 
et al., 2001; Waterhouse et al., 1993). Similarly, efferent topography also exists, to 
some extent, within the locus coeruleus and also some measure of modality-
129
specificity (Berridge and Waterhouse, 2003; Waterhouse et al., 1993). Furthermore, 
spatially directed expectation of pain has been shown to induce a specific placebo 
effect only on the part of the body where pain is expected (Benedetti et al., 1999).
This effect was abolished by naloxone indicating that it is an opioid-mediated effect 
which is targeted towards a particular part of the body. A recent PET study 
demonstrated the involvement of the brainstem in the placebo response although there 
was no activation in response to pain only (Petrovic et al., 2002). This gives further 
credence to the notion that somatotopy exists in the brainstem systems.
It is also possible that the regional specificity of the allodynia or pain is mediated at a 
higher level than the brainstem i.e. thalamus or cortex. The spread of the pain or 
allodynia could be a result of increasing receptive fields due to central sensitisation at 
the third-order level i.e. thalamus. One could postulate that this sensitisation occurs as 
result of the increasing sensory traffic which is secondary to the disinhibition arising 
from the brainstem modulatory systems. In rats dorsal raphe stimulation has been 
shown to modulate the firing rate of thalamic parafascicular neurons to noxious 
stimuli (Andersen and Dafny, 1983) supporting the view that ascending modulation of 
nociceptive information also occurs and may be mediated by the brainstem. One could 
also extend this theory of brainstem-mediated facilitation of thalamic processing to 
the symptoms of photophobia and phonophobia.
Alternatively, there is an argument that the thalamus itself is a possible candidate for 
the area of dysfunction in migraine. It is involved in nociceptive pathways and is 
responsible for integration of sensory information and, as such, could be involved in 
altering the gating of such information. In fact, it was recently demonstrated that 
propranolol inhibits trigeminal nociception at thalamocortical neurons (Shields and 
Goadsby, 2004). However, as the evidence from functional imaging studies of
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thalamic involvement in migraine is inconsistent further discussion regarding the role 
of the thalamus falls beyond the scope of this thesis.
Laterality
The ipsilateral findings in our induced migraine PET study are in keeping with the 
known anatomy of the descending nociceptive pathways, namely the ipsilateral 
pathways descending from the PAG to the TNC. Kaube et al found facilitation of the 
nociception-specific blink reflex response predominated on the headache side only 
during migraine (Kaube et al., 2002).
How does one explain the discrepancy in laterality between the Weiller study and 
between the two studies described in this thesis? There are a number of differences 
between Weiller’s study and the induced migraine study. First, Weiller only included 
subjects with migraine without aura whereas we included subjects both with and 
without aura. Secondly, three of their subjects were taking migraine prophylaxis (p- 
blockers) at the time of the study. Thirdly, all their subjects had right-sided headache. 
The lack of left-sided or bilateral migraine subjects makes it difficult to derive 
inferences regarding laterality. Fourthly, they looked at spontaneous rather than 
induced migraine and so the likelihood is that the subjects were imaged later on in the 
attack, as was the case with our spontaneous migraine study. Also, they did not 
include a control group to account for an order effect. Unlike our induced migraine 
study neither the Weiller study nor our spontaneous migraine study were designed 
specifically to look for laterality. It may be possible that the brainstem activation 
changes from unilateral to bilateral / contralateral as the migraine evolves. In fact, in a 
clinical report looking at the evolution of allodynia during migraine it was 
demonstrated that one hour into the migraine the allodynia was ipsilateral to the
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headache but this started to affect the contralateral side of the head after two hours 
(Burstein et al., 2000). One could postulate that the allodynia was a response to the 
dysfunction of the gating mechanism of the brainstem nociceptive structures leading 
to sensitisation at the TNC. If this is the case then the development of allodynia on the 
contralateral side later on in the attack would imply that there was dysfunction of the 
contralateral brainstem later on in the attack. Clinical observations suggest that side- 
shift can occur during migraine. In fact even though 62 % of migraineurs are thought 
to have unilateral headache only 17-21% have side-locked headache (Leone et al., 
1993; Selby and Lance, 1960). It is unclear from the Weiller study to what extent 
laterality of headache was examined in the subjects and whether they were subjects 
who had side-locked headache or whether they experienced side-shift or any bilateral 
component to the headache at any point during the migraine. Our patients were 
recruited on the basis of their headache laterality and this was closely monitored and 
documented throughout the study.
The activation seen in functional imaging studies may represent activation of 
excitatory or inhibitory neurons. In certain parts of the descending nociceptive 
modulatory pathway the cells are segregated into “on” or “o ff’ cells (Morgan and 
Fields, 1994). It may be that that this functional segregation enables one group to be 
preferentially activated during migraine.
Alternatively, if no side shift has occurred, the late activation in the contralateral 
brainstem may be accounted for by the fact that reciprocal inhibitory pathways exist 
between right and left locus coeruleus (LC) (Buda et al., 1975). The early dysfunction 
on the ipsilateral side may lead to loss of inhibition of the contralateral LC which 
consequently becomes overactive. The ipsilateral LC gradually normalises but central
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sensitisation has become established resulting in a continuation of the symptoms 
which takes longer to resolve.
Which specific region of the brainstem could be responsible?
The noradrenergic system, in particular the locus coeruleus (LC) is an ideal candidate. 
If one considers the functions of this system the relevance to migraine becomes 
apparent. Noradrenaline acts as a neuromodulator enhancing the signal to noise ratio. 
It modulates the level of attention and arousal. Higher levels of tonic activity of LC 
neurons are associated with higher levels of arousal (there is virtual quiescence during 
REM sleep) and the discharge rates anticipate changes in behavioural state (Foote et 
al., 1980). Phasic discharges occur in response to novel stimuli and the LC shows 
plasticity of response as a function of changing significance of stimuli (Sara and 
Segal, 1991). The LC is involved in modulation of sensory information. Lesions of 
the LC have been shown to affect auditory event-related potentials in primates 
(Pineda et al., 1989). In vitro noradrenaline induces a shift in the firing pattern of 
cortical and thalamic neurons (McCormick, 1989). In a study applying non-noxious 
electrical stimuli to the trigeminal region of unanaesthetised rats (whisker pad), 
neuronal activity was recorded from the thalamus and cortex before and during tonic 
and phasic stimulation of the LC (Berridge and Waterhouse, 2003). The activity was 
enhanced by LC stimulation in an inverted-U response. In some cases, LC stimulation 
resulted in responses to otherwise subthreshold synaptic input and in other cases it 
decreased the mean response latency. These results demonstrate that LC output can 
optimise information processing within sensory circuits and can simultaneously 
facilitate stimulus-evoked discharge patterns at multiple levels of an ascending
133
sensory network. Similarly, in the auditory system both the auditory cortex and 
cochlear nuclei receive noradrenergic innervation solely from the LC which exerts a 
synergistic effect at both sites by filtering afferent information in a way which favours 
stronger signals (Pickles, 1976). A similar effect of the LC on the visual system has 
been reported (Kasamatsu, 1991) including the noradrenergic modulation of activity 
in the lateral geniculate nucleus (Funke et al., 1993). This could explain the symptoms 
of photophobia and phonophobia. The role of the brainstem noradrenergic system in 
the descending modulation of nociception has already been discussed in chapter 1.
The response to stress is also relevant to migraine as stress or relaxation after stress is 
a classical trigger. Evidence suggests that corticotropin-releasing hormone (CRH) 
inputs to the LC from the medulla and amygdala may activate the LC in response to 
physiological and environmental stressors (Van Bockstaele et al., 1996; Van 
Bockstaele et al., 1998). Fos induction has been demonstrated in the LC and dorsal 
raphe in response to stress in rats (Ishida et al., 2002). There is also a projection from 
the hypocretin-containing neurons in the lateral hypothalamus to the LC (Peyron et 
al., 1998). Both CRH and hypocretin are implicated in stress and arousal-related 
processes. Hypocretin (orexin) activates LC neurons to increase the frequency of 
action potentials (Horvath et al., 1999). It is thought to be involved in appetite, 
neuroendocrine and autonomic regulation, sleep and, more recently, pain. Triggers 
other than stress may also involve the LC. Nitric oxide is thought to be involved in 
modulating excitatory activity in the LC (Pineda et al., 1996; Xu et al., 1998). This is 
discussed in the next section.
There is good evidence for the involvement of the serotonergic system in migraine 
(see chapter 1). The serotonergic system displays circadian rhythmicity under the
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control of the suprachiasmatic nucleus of the hypothalamus. The SCN also receives 
afferent input from the DR (Zurak, 1997). The DR discharge pattern during the sleep- 
wake cycle is similar to that of the LC in that it is active during wakefulness and 
quiescent during REM sleep. There is evidence that selective attention in the auditory 
system is modulated by serotonin (Ahveninen et al., 2003) and brainstem auditory 
evoked potentials have been shown to be modulated by the serotonergic system 
(Bank, 1991; Sand and Vingen, 2000). Another electrophysiological measure, the 
intensity dependence of auditory evoked potentials (IDAP), which is abnormal inter- 
ictally in migraineurs (Wang et al., 1996) is also modulated by serotonergic 
modulators such as dexfenfluramine and triptans (Proietti-Cecchini et al., 1997). The 
IDAP is thought to be related to central serotonergic transmission. The pivotal role of 
the brainstem serotonergic nuclei in the descending inhibition of nociception has been 
described in chapter 1.
There is likely to be considerable overlap between the serotonergic and noradrenergic 
systems. Indeed, there is a dense innervation of the LC by serotonergic fibres (Pickel 
et al., 1977) and reciprocal connections have been demonstrated in animals (Kim et 
al., 2004). It is likely that both systems regulate modulation of sensory input. In rat 
visual cortex the two function in a complementary manner by modulating single 
neuron responses to visual stimuli (Waterhouse et al., 1990). Noradrenaline increases 
the signal-to-noise ratio whereas serotonin decreases it in this example. Both systems 
are linked to the hypothalamus, serotonin to the suprachiasmatic nucleus and the LC 
to the lateral hypothalamus and indirectly to the suprachiasmatic nucleus (Aston- 
Jones et al., 2001). As mentioned above both the DR and the LC demonstrate Fos 
induction in response to stress (Ishida et al., 2002). The serotonergic system is
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involved in mood disorders such as depression. The LC receives inputs from the 
limbic system (the amygdala) suggesting that mood and emotional status can have an 
effect on LC activity and the noradrenergic system is thought to have at least a 
modulatory role in depression. Both systems are also affected by the sleep-wake cycle 
and there is a well described relationship between sleep and migraine (Sahota and 
Dexter, 1990). In fact, migraine has been shown to occur in association with stage 3, 4 
and REM sleep stages which are when the LC and DR are less active. Both systems 
also have effects on cerebral vasculature and nociception (as described in chapter 1). 
Together, these observations suggest that the brainstem serotonergic and 
noradrenergic systems are ideally suited to respond to migraine triggers and to play a 
significant role in the clinical manifestations of migraine.
Nitric oxide, the brainstem and migraine
The role of nitric oxide in migraine has been discussed in chapter 4. Nitric oxide 
synthase has been found to be distributed throughout the brain. Focussing on the 
brainstem, it has been demonstrated that in rats the DR provides a source of NO for 
cortical and subcortical regions including the thalamus and trigeminal nucleus and 
that serotonin and NO are co-localised in certain regions of the DR (Simpson et al., 
2003) although this may be species specific. It is also known that the DR sends 
projections to the occipital cortex (Wilson and Molliver, 1991). It is possible that 
these projections may be involved in the GTN-triggering of migraine with aura.
As mentioned earlier, subcutaneous GTN has been found to produce a significant 
increase of nitric oxide synthase (NOS) and Fos protein-like immunoreactivity in the 
trigeminal nucleus caudalis (Pardutz et al., 2000) and brainstem nuclei, including the 
LC (Tassorelli and Joseph, 1995) in rats. The temporal profile of neuronal activation
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following GTN shows that neuronal activation begins as early as 60 minutes post­
injection in brain areas controlling cardiovascular function and reaches maximum 
expression 3 hours later in nociceptive structures (Tassorelli and Joseph, 1995). This 
time course suggests GTN has an initial effect on brain vascular centres which is later 
followed by the nociceptive effect. Further evidence for this is provided by a study 
involving GTN administration to rats followed by measurements of monoamine levels 
(Tassorelli et al., 2002). This showed that at 4 hours there was a decrease in brainstem 
levels of serotonin. In animal studies serotonin depletion has been shown to result in 
hypersensitivity of the cranial vascular system to NO (Srikiatkhachom et al., 2000). 
Lower basal platelet serotonin concentration appears to increase the susceptibility to 
develop migraine (Juhasz et al., 2003). The effect of NO on serotonin release has been 
investigated in a few brain areas with varying results. However in the raphe nuclei 
(Smith and Whitton, 2000) and hypothalamus (Kaehler et al., 1999) NO exerts an 
inverse concentration effect on serotonin release: low concentrations decrease 
serotonin release and high concentrations have the opposite effect. There is further 
evidence for an interaction between the serotonergic system and the NO system. The 
5 -H T ib/id receptor agonist, sumatriptan, attenuates the effect of GTN on cerebral 
blood flow and on nNOS expression in the TNC and trigeminal ganglion, thus 
modulating NO synthesis (Suwattanasophon et al., 2003). It is possible that this 
interaction between NO and serotonin may be responsible for GTN triggered migraine 
with aura since serotonergic projections to the occipital cortex may also be modulated 
by NO.
NOS containing neurons have been described in the region of the LC in rats (Xu et al.,
1994). NO has a been shown to reduce the amplitude of excitatory post-synaptic
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currents in LC neurons (Xu et al., 1998) although another group (Pineda et al., 1996) 
reported that NO donors cause an increase in firing rate in LC neurons. The 
discrepancy between these two studies was put down to methodological differences 
(Xu et al., 1998). Both studies suggest that NO may have a modulatory effect on LC 
neurons.
As mentioned earlier, there are well described connections between the hypothalamus 
and brainstem which may be important in the triggering of migraine. Furthermore, 
many of the typical premonitory symptoms of migraine can be thought of as 
originating in the hypothalamus. For example, one of the main pathways involved in 
yawning originates in the paraventricular nucleus (PVN) of the hypothalamus and NO 
is thought to mediate this in response to activation of the oxytocinergic neurons by 
dopamine and other substances (Argiolas and Melis, 1998). These neurons are thought 
to project to other areas including the brainstem. In addition to yawning, it has been 
postulated that NO is involved in generating circadian rhythms in the suprachiasmatic 
nuclei which has implications in terms of “spontaneous” triggering of migraine 
(Golombek et al., 2004). Other common premonitory symptoms of migraine include 
thirst, polydipsia and polyuria. Following GTN administration in rats Fos activation 
was seen in the PVN and supraoptic nuclei (SON) of the hypothalamus (Tassorelli 
and Joseph, 1995). NO has been shown to inhibit the electrical activity of vasopressin 
and oxytocin neurons in the SON and PVN (Kadekaro, 2004). NOS and its mRNA are 
expressed in the osmoregulatory networks (Wang and Morris, 1996).
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Clearly an important question, which remains as yet unanswered, relates to the 
mechanism of triggering in migraine. NO has established itself as a reliable and 
reproducible trigger, although the mechanism for this has not yet been determined.
It may be that the hypothalamus is involved in the triggering process although not 
necessarily exclusively. What appears to be more likely is that the final common 
pathway is in the brainstem. Certain predisposing conditions may make one more 
susceptible to triggering; for example, serotonin depletion (Srikiatkhachom et al., 
2000) and oestrogen (Pardutz et al., 2002; Sarchielli et al., 1996) alter the sensitivity 
to NO. As mentioned earlier, the LC receives a dense serotonergic innervation (Pickel 
et al., 1977). Under resting conditions, NOS inhibition does not appear to influence 
serotonin release in the rat LC. However, under conditions of stress NO appears to 
facilitate serotonin release in this region (Sinner et al., 2001). This finding is 
interesting as it suggests that a NO-mediated event may only occur under conditions 
of increased susceptibility.
It is clear that migraineurs and controls respond differently to NO donors. There is 
evidence that migraineurs exhibit greater intracranial artery sensitivity to NO than 
controls (Thomsen et al., 1993). In fact, it is likely that this inherent sensitivity 
extends to the entire trigeminovascular system and not only in relation to nitric oxide 
(Katsarava et al., 2003b; Weissman-Fogel et al., 2003).
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Figure 10.2 fMRI showing activation in trigeminal nuclei regions in response to 
noxious heat stimuli (DaSilva et al., 2002).
Yellow, red, blue correspond to V2,V3,V1 respectively
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Weiller et al., 1995 
(spontaneous migraine)
Bahra et al., 2001 
(induced migraine)
Afridi et al., 2004a 
(spontaneous migraine)
Matharu et al., 2004a 
(chronic migraine)
Afridi et al., 2005 
(induced migraine)
Matharu et al. 2004b 
(hemicrania continua)
Figure 10.3 Brainstem activation in migraine (and hemicrania continua)
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PART V. CONCLUSION
Migraine is a complex neurobiological disorder which cannot simply be explained by 
dysfunction in one area of the brain in isolation. The very nature of the complex and 
intricate pathways involved in neural processing would make this highly unlikely. The 
PET findings of brainstem activation during migraine presented in this thesis do not 
necessarily imply a causal link. However when one takes into the account the growing 
body of evidence which supports a pivotal role for the brainstem in migraine these 
findings become more significant in such a context. The demonstration of the 
relationship between laterality of the clinical symptoms and functional neuroanatomy 
also increases the validity of these findings. This does not exclude the possibility that 
other regions of the brain, for example the thalamus, may also have an important role 
to play either as part of the trigeminal sensory and nociceptive pathways or in its own 
right. Perhaps as the technology advances the picture will become clearer.
The GTN model of migraine has proven to be a reliable and reproducible model 
which has facilitated the further study of migraine.
To conclude, functional imaging is a valuable tool which, as I hope has been 
demonstrated, has enhanced our understanding of this complex and challenging 
condition.
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APPENDIX
IHS diagnostic criteria (Headache Classification Committee of The 
International Headache Society, 2004)
Migraine without aura 
Diagnostic criteria:
A. At least 5 attacks fulfilling B - D.
B. Headache attacks lasting 4-72 hours and occurring < 15 days/month (untreated 
or unsuccessfully treated).
C. Headache has at least two of the following characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical activity 
(i.e., walking or climbing stairs)
D. During headache at least one of the following:
1. Nausea and/or vomiting
2. Photophobia and phonophobia
E. Not attributed to another disorder
Typical aura with migraine headache 
Diagnostic criteria:
A. At least two attacks fulfilling criteria B -  E
B. Fully reversible visual and/or sensory and/or speech symptoms but no motor 
weakness
C. At least 2 of 3:
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1. Homonymous visual symptoms including positive features (i.e. 
flickering lights, spots, lines and/or negative features (i.e. loss of 
vision) and/or unilateral sensory symptoms including positive features 
(i.e. pins and needles) and/or negative features (i.e. numbness)
2. At least one symptom develops gradually over >5 minutes and/or 
different symptoms occur in succession
3. Each symptom lasts >5 minutes and < 60 minutes
D. Headache that meets criteria B-D for migraine without aura begins during the 
aura or follows aura within 60 minutes
E. Not attributed to another disorder
Persistent aura without infarction
Description: Aura symptoms persist for more than 2 weeks without radiographic 
evidence of infarction.
Diagnostic criteria:
A. The present attack in a patient with migraine with aura is typical of previous
attacks but one or more aura symptoms persist for more than one week
B. Not attributed to another disorder
Familial hemiplegic migraine 
Diagnostic criteria:
A. At least 2 attacks fulfilling B -  E
B. Fully reversible motor weakness and at least one of the following other fully
reversible aura symptoms: visual, sensory or speech disturbance.
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C. At least two of the following:
1. At least one aura symptom develops gradually over > 5 minutes and/or 
different symptoms occur in succession.
2. Each aura symptom lasts > 5 minutes and less than 24 hour.
3. Headache that meets criteria B-D for migraine without aura begins 
during the aura or follows aura within 60 minutes.
D. At least one first or second-degree relative has migraine attacks with aura 
including motor weakness (fulfils criteria A, B, C and E).
E. Not attributed to another disorder.
Sporadic hemiplegic migraine 
Diagnostic criteria:
A. At least 2 attacks fulfilling B - D
B. Fully reversible motor weakness and at least one of the following other aura 
symptoms: visual, sensory or speech disturbance.
C. At least two of the following:
1. At least one aura symptom develops gradually over > 5 minutes and/or 
different symptoms occur in succession.
2. Each aura symptom lasts less than 24 hour.
3. Headache that meets criteria B-D for migraine without aura begins 
during the aura or follows aura within 60 minutes.
D. No first or second degree relative has migraine attacks with aura including 
motor weakness.
E. Not attributed to another disorder.
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